Many cultures use the fruit and its juices as a traditional folk remedy to treat or prevent various ailments.

Modern research has linked pineapple juice and its compounds to health benefits, such as improved digestion and heart health, reduced inflammation, and perhaps even some protection against cancer. However, not all evidence has been conclusive.

Here are 7 science-based benefits of pineapple juice, based on the current research.

1. Rich in Nutrients

Pineapple juice provides a concentrated dose of various nutrients. One cup (240 mL) contains around:

• Calories: 132
• Protein: less than 1 gram
• Fat: less than 1 gram
• Carbs: 33 grams
• Sugars: 25 grams
• Fiber: less than 1 gram
• Manganese: 55% of the Daily Value (DV)
• Copper: 19% of the DV
• Vitamin B6: 15% of the DV
• Vitamin C: 14% of the DV
• Thiamine: 12% of the DV
• Folate: 11% of the DV
• Potassium: 7% of the DV
• Magnesium: 7% of the DV

Pineapple juice is particularly rich in manganese, copper, and vitamins B6 and C. These nutrients play an important role in bone health, immunity, wound healing, energy production, and tissue synthesis.

It also contains trace amounts of iron, calcium, phosphorus, zinc, choline, and vitamin K, as well as various B vitamins.

Summary

Pineapple juice is rich in a variety of vitamins and minerals. It's especially packed with manganese, copper, vitamin B6, and vitamin C all of which play important roles in the proper functioning of your body.

2. Contains Additional Beneficial Compounds

In addition to being rich in vitamins and minerals, pineapple juice is a good source of antioxidants, which are beneficial plant compounds that help keep your body healthy.

Antioxidants help neutralize unstable compounds known as free radicals, which can build up in your body due to factors like pollution, stress, or an unhealthy diet and cause cell damage.

Experts believe that the antioxidants in pineapple juice, particularly vitamin C, beta carotene, and various flavonoids, are in large part to thank for its potential beneficial effects.

Pineapple juice also contains bromelain, a group of enzymes linked to health benefits, such as reduced inflammation, improved digestion, and stronger immunity.

Summary

Pineapple juice is rich in antioxidants, which help protect your body from damage and disease. It also contains bromelain, a group of enzymes that may reduce inflammation, improve digestion, and boost immunity.

3. May Suppress Inflammation

Pineapple juice may help reduce inflammation, which is believed to be the root cause of many chronic diseases.

This may largely be due to its bromelain content. Some research suggests that this compound may be as effective as non-steroidal anti-inflammatory drugs (NSAIDs) but with fewer side effects.

In Europe, bromelain is approved for use to reduce inflammation caused by trauma or surgery, as well as to treat surgical wounds or deep burns.

In addition, there's evidence that ingesting bromelain before surgery may help reduce the level of inflammation and pain caused by surgery.

Some studies further suggest that bromelain may help reduce pain and inflammation caused by a sports injury, rheumatoid arthritis, or osteoarthritis of the knee.

That said, research has yet to test the direct effects of pineapple juice on inflammation.

Therefore, it's unclear whether the bromelain intakes achieved through drinking small to moderate amounts of pineapple juice would provide the same anti-inflammatory benefits as those observed in these studies.

Summary

Pineapple juice contains bromelain, a group of enzymes that may help reduce inflammation caused by trauma, injuries, surgery, rheumatoid arthritis, or osteoarthritis. However, more juice-specific studies are needed.

4. May Boost Your Immunity

Pineapple juice may contribute to a stronger immune system.

Test-tube studies suggest that bromelain, a mixture of enzymes naturally found in pineapple juice, may activate the immune system.

Bromelain may also improve recovery from infections, such as pneumonia, sinusitis, and bronchitis, especially when used in combination with antibiotics.

However, most of these studies are dated, and none have examined the immunity-boosting effects of pineapple juice in humans. Therefore, more research is needed to confirm these results.

Summary

Some research suggests that pineapple juice may contribute to a stronger immune system. It may also help increase the effectiveness of antibiotics. However, more studies are needed before strong conclusions can be made.

5. May Help Your Digestion

The enzymes in pineapple juice function as proteases. Proteases help break down protein into smaller subunits, such as amino acids and small peptides, which can then be more easily absorbed in your gut.

Bromelain, a group of enzymes in pineapple juice, may particularly help improve digestion in people whose pancreas cannot make enough digestive enzymes a medical condition known as pancreatic insufficiency.

Animal research suggests that bromelain may also help protect your gut from harmful, diarrhea-causing bacteria, such as E. coli and V. cholera.

Moreover, according to some test-tube research, bromelain may help reduce gut inflammation in people with inflammatory bowel disorders, such as Crohn's disease or ulcerative colitis.

That said, most studies have investigated the effect of concentrated doses of bromelain, rather than that of pineapple juice, and very few were conducted in humans. Therefore, more research is needed.

Summary

The bromelain in pineapple juice may aid digestion, guard against harmful, diarrhea-causing bacteria, and reduce inflammation in people with inflammatory bowel disorders. However, more research is needed.

6. May Promote Heart Health

The bromelain naturally found in pineapple juice may also benefit your heart.

Test-tube and animal studies suggest that bromelain may help reduce high blood pressure, prevent the formation of blood clots, and minimize the severity of angina pectoris and transient ischemic attacks two health conditions caused by heart disease.

However, the number of studies is limited, and none are specific to pineapple juice. Therefore, more research is needed before strong conclusions can be made.

Summary

Some research links the bromelain naturally found in pineapple juice to markers of improved heart health. However, more pineapple-juice-specific studies are needed.

7. May Help Fight Certain Types of Cancer

Pineapple juice may have potential cancer-fighting effects. Again, this is likely in large part due to its bromelain content.

Some studies suggest that bromelain may help prevent the formation of tumors, reduce their size, or even cause the death of cancerous cells.

However, these were test-tube studies using concentrated amounts of bromelain that were much higher than those you'd ingest from drinking a glass of pineapple juice. This makes it difficult to project their results to humans.

Therefore, more research is needed before strong conclusions can be made.

Summary

Test-tube studies suggest that concentrated amounts of bromelain may help protect against cancer. However, it's currently unclear whether pineapple juice offers similar benefits in humans.

Possible Precautions

Pineapple juice is generally considered safe for most people.

That said, bromelain, a group of enzymes naturally found in pineapple juice, may enhance the absorption of certain drugs, especially antibiotics and blood thinners.

As such, if you are taking medications, consult your physician or registered dietitian to make sure it's safe to consume pineapple juice.

This beverage's acidity may also trigger heartburn or reflux in some people. Specifically, those with gastroesophageal reflux disease (GERD) may want to avoid consuming large amounts of this beverage.

Despite its potential benefits, it's important to remember that pineapple juice remains low in fiber yet high in sugar.

This means it's unlikely to fill you up as much as eating the same quantity of raw pineapple would. Therefore, it may promote weight gain in some people.

What's more, while drinking small amounts of juice has been linked to a lower risk of type 2 diabetes and heart disease, drinking more than 5 ounces (150 mL) per day may have the opposite effect.

Therefore, it's likely best to avoid drinking too much pineapple juice, and when you do, stick to 100% pure varieties that are free of added sugars.

Summary

Pineapple juice is low in fiber yet rich in sugar, and drinking too much may lead to weight gain or disease. This beverage may also interact with medications and trigger heartburn or reflux in some people.

The Bottom Line

Pineapple juice contains a variety of vitamins, minerals, and beneficial plant compounds that may protect you from disease.

Studies link this beverage to improved digestion, heart health, and immunity. Pineapple juice or its compounds may also help reduce inflammation and perhaps even offer some protection against certain types of cancer.

However, human studies are limited, and it's unclear whether the effects observed in test tubes or animals can be achieved by small daily intakes of pineapple juice.

Moreover, this beverage remains low in fiber and rich in sugar, so drinking large quantities each day is not recommended.

From Your Site Articles

Related Articles Around the Web

See more here:
Why COVID-19 Is Hitting Men Harder Than Women - EcoWatch

Recommendation and review posted by Bethany Smith

The Judges of Yolo County Superior Court prior to Dan Wolks appointment

Even before this week, Yolo Countys bench seemed out of step with the rest of the state. For the last 13 years, according to various media sources, Californias bench has become more diversemore women, more people of color. Not Yolo County.

Yolo County is moving in the opposite direction with 8 white men and two women, one of whom is Latina. That was before Tuesday when Governor Newsom made what appears to be the latest appointment based on political connections.

Dan Wolk as you know is the former Mayor of Davis, having served from 2014 to 2016. In both 2014 and 2016, he ran for State Assembly and lost, first to Bill Dodd and then to Cecilia Aguiar-Curry. His professional experience is a little over a decade working for the Solano County Counsels office.

He has limited trial experience and his chief qualifications appear to be the fact that his mother is a retired State Senator and his father is a retired Dean of the UC Davis Law School.

Dan Wolk appears to be the latest Yolo County appointment that is based more on who someone is than their qualifications to be judge. Thats not fair to Dan Wolk and this issue did not begin with Governor Gavin Newsomit is a trend.

And it is a problem for the diversity on the Yolo County bench, which now has 9 white men in a county where whites only make up 46 percent of the total population, according to 2019 census estimates.

Indeed, if you look at Governor Newsoms judicial appointments overall on Tuesday, people wanting diversity would applaud them.

In March of 2019 after Governor Jerry Brown stepped down, a survey found that for the 13th straight year, Californias judicial bench has grown more diverse, according to new data released by the Judicial Council.

Governor Browns appointments, including the nearly 200 appointments made in his final year in office: women accounted for more than half of those appointees, and 41 percent identified as non-white.

Governor Newsom continued that trend as last year, his first, he appointed a majority of women and nonwhites to the bench.

That continued on Tuesday.Governor Newsom appointed 14 people to the bench8 women and just two white males.

So why is Yolo County different than other counties?

A big part has to do with its location, roughly 15 minutes from the State Capitol on the other side of the Sacramento River.

It is a small county, but it is prominentthe home of UC Davis, a major law school and academic center. Davis also happens to be the home of a number of State Capitol employees and staffers.

The problem here is actually very clear, and it goes back to the last six governor appointments to the bench starting in 2008.

In 2008, Governor Arnold Schwarzenegger appointed employment lawyer Samuel McAdam.In 2010, he appointed Dan Maguire, who was his deputy legal affairs secretary.

In 2012, Janene Beronio, one of the two women on the bench, was elected when retiring Judge Stephen Mock stepped down at the end of his term.

In 2015, Governor Brown appointed Sonia Corts, the first Latina to be judge in Yolo County.

In 2018, he appointed Tom Dyer and Peter Williams, both of whom were attorneys in his administration.

Now, in 2020, Governor Newsom appoints Dan Wolk, the former Mayor of Davis and the son of State Senator Lois Wolk.

While the 2018 appointees did not live in Yolo County, Sam McAdam, Dan Maguire, and Dan Wolk all live in Davis and Sonia Corts lived in Woodland.

A key question is why has Yolo County become the place where governors stick their legal counsel when they wish to award them with appointments?

Clearly, being near the capital is to Yolo Countys detriment. Clearly Yolo County lacks a deep bar association that is diverse. But we also know for a fact that there were very qualified women and women of color who have put their hats in the ring and got passed over in the last three appointments.

Is no one at the governors office paying attention to the bench in Yolo for ethnic make up?

One thing that has shifted in the last three appointmentsthe partisan make up of the bench. For a long time, not only was the bench white and male, but it was also disproportionately Republican. This is a heavily Democratic County, as two-thirds of the voters in 2016 voted for Hillary Clinton.

Now five of the 11 judges were appointed by DemocratsDave Rosenberg by Gray Davis in 2003, and the three most recent appointments by Jerry Brown with Dan Wolk by Gavin Newsom.

This isnt about whether or not Dan Wolk will be a good judge; he will be a judge, and hopefully he does well. This really isnt about him. It is about the process. The fact is that governors in recent years have done a good job of creating a much more diverse bench in California, and my only complaint is that when it comes to Yolo County, we have been shortchanged.

Nine white male judges in this era with 10 years of Democratic governors should not happen.

With all due respect to the last three appointments, Yolo County deserves better than to get a rash of political appointments with little regard to the overall lack of diversity of its bench.

Contrast that to San Francisco which in March elected three progressive women to its bench.It is hard to imagine two more different judicial environments, and given the notion of equal justice under the law and the fact that the vast majority of criminal defendants in Yolo County are black and browna disproportionate number, mind youit would seem that a bench more reflective of the population demographics would be fairer.

David M. Greenwald reporting

To sign up for our new newsletter Everyday Injustice https://tinyurl.com/yyultcf9

Link:
My View: Dan Wolk's Appointment to Judge Further Skews Yolo's Bench - The Peoples Vanguard of Davis

Recommendation and review posted by Bethany Smith

Male hypogonadism is a failure of the testes that produce the male test hormone testosterone, sperm, or both. It can be due to a testicular disorder or the result of a disease process involving the hypothalamus and pituitary gland. The male hypogonadism market is anticipated to grow owing to increasing case of testosterone deficiency among men. However, high side effects is one of the major restraints for the market growth. Moreover, rising geriatric population all across the world coupled with rising cases of obesity and rheumatoid arthritis are expected to benefit the growth of the market in the forecast period.

Some of the key players of Male Hypogonadism Market:AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Finox Biotech,, Laboratoires Genevrier, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.

Get Sample Copy of this Report @ https://www.reportsweb.com/inquiry&RW00013261048/sample

The Global Male Hypogonadism Market research report offers an in-depth analysis of the global market, providing relevant information for the new market entrants or well-established players. Some of the key strategies employed by leading key players operating in the market and their impact analysis have been included in this research report.

Segmentation by product type:Klinefelters Syndrome

Kallmann Syndrome

Pituitary Disorders

Others

Segmentation by Drug Delivery:Topical Gels

Injectable

Transdermal Patches

Others

Get Discount for This Report @ https://www.reportsweb.com/inquiry&RW00013261048/discount

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Male Hypogonadism market based on product and application. It also provides market size and forecast till 2027 for overall Male Hypogonadism market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM), which is later sub-segmented by respective countries and segments.

Fundamentals of Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Male Hypogonadism Market Size2.2 Male Hypogonadism Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Male Hypogonadism Market Size by Manufacturers3.2 Male Hypogonadism Key Players Head office and Area Served3.3 Key Players Male Hypogonadism Product/Solution/Service3.4 Date of Enter into Male Hypogonadism Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Male Hypogonadism Sales by Product4.2 Global Male Hypogonadism Revenue by Product4.3 Male Hypogonadism Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Male Hypogonadism Breakdown Data by End User

Continue for TOC

Purchase This Report @ https://www.reportsweb.com/inquiry&RW00013261048/buying

About ReportsWeb:ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Read the original:
Recent Facts that led Male Hypogonadism Market on top by 2027 with Top Key Players like AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG, Eli...

Recommendation and review posted by Bethany Smith

The global Male Hypogonadism Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Male Hypogonadism Therapy market player in a comprehensive way. Further, the Male Hypogonadism Therapy market report emphasizes the adoption pattern of the Male Hypogonadism Therapy across various industries.

The Male Hypogonadism Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Male Hypogonadism Therapy market provides a birds eye view of the current proceeding within the Male Hypogonadism Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Male Hypogonadism Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2619190&source=atm

The key players covered in this studyEli LillyPfizerAbbVieNovo NordiskMerck KGaAMylanBayerTevaNovartisAbbottRocheEndo InternationalIpsenANI PharmaceuticalsTherapeuticsMD

Market segment by Type, the product can be split intoParenteralTransdermalOralOthersMarket segment by Application, split intoHospitalsDrugstoresOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Male Hypogonadism Therapy status, future forecast, growth opportunity, key market and key players.To present the Male Hypogonadism Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Male Hypogonadism Therapy are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2619190&source=atm

The Male Hypogonadism Therapy market report offers a plethora of insights which include:

The Male Hypogonadism Therapy market report answers important questions which include:

The Male Hypogonadism Therapy market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2619190&licType=S&source=atm

Why Choose Male Hypogonadism Therapy Market Report?

Male Hypogonadism Therapy Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See original here:
Addressing the potential impact of coronavirus disease (COVID-19) on Male Hypogonadism Therapy Market : Future Growth and Challenges Analyzed Aminet...

Recommendation and review posted by Bethany Smith

For Avilez, the difficult adjustment is not just the result of the time she spent in prison and detention, but that she's back in her aunts house trying to live her life authentically in close quarters with some family members who haven't seen her since she transitioned to female.

"My aunt still calls me mijo. It's kind of hard for her, and I understand that. I'll have to sit down and talk with her about that later," Avilez said. "But, I want to be able to wear my makeup. I don't have to be scared no more."

Avilez lost an initial bid for asylum, but she has appealed. While she awaits her next immigration court hearing, she said she's eager to get her life started again. She wants to get a cellphone, so that she can call the friends she made in detention.

She also wants to get her job back. Avilez said she used to work in the medical field as a service technician, helping people who use wheelchairs and providing assistance to the elderly across Monterey County.

"I'm happy I'm free. [Though] I don't feel completely free because I'm wearing an ankle monitor ... I can't go out, she said.

Since Avilez left ICE custody, she has not had access to hormone treatment. But attorney Hector Vega of the San Francisco Public Defender's Office, who represents Avilez in her immigration case, said social workers in his office have found a clinic in Monterey County that can provide her the medication, free of charge.

In her first act of independence since being released from detention, Avilez bought a pink T-shirt with a single parentheses in the middle and colons dotting either side, creating the image of both a sad and happy face.

"Is it a happy face? Avilez asked. You decide if it's happy or not."

Continued here:
Released From ICE Detention Into a Pandemic: For One Woman, Returning Home Is Complex - KQED

Recommendation and review posted by Bethany Smith

Beauty, business, relax, repeat: Its all in a days work for British Beauty Council CEO Millie Kendall, MBE.

Subtle TweaksI totally rate Dr. Jules Nabet for tweakments. He is based at Omniya in Knightsbridge. He is a hormone specialist as well and really understands a womans face. Dr. Alexis Granite at Mallucci London is pretty incredible, too. I have watched her work and she is extremely light-handed if you want subtlety.

Freeze Frame My favorite facial would be with Su-Man Hsu at the W Hotel. She is Taiwanese, a former dancer and lives near me. She has really become a friend. Su-Man has the most unique massage techniqueit is like your face wakes up after having been asleep for years. I can top up my facials with a Bioeffect rejuvenating facial at Apogii in Notting Hill. They also have a cryo clinic and its a double-chambered one. Call me a sucker, but three minutes at minus 110 degrees Celsius can do wonders for your body. Plus, it is large enough so you can take some friends in with you for moral support.

Charlotte Tilbury, of course, the darling of British Beauty; Pat McGrath Labs, the mother of British Beauty; Aromatherapy Associates is simply my favorite bath and body brand. Deep Relax is divine and the most recognizable, but equally unique, scent.

Destination: RelaxationMy favorite massage is a deeply relaxing Aromatherapy Associates full body with Rika at the Mandarin Oriental Hotel. The spa is just so chic.

One-Stop Shop For workouts, I have a personal trainer, but I love the Reformer Pilates classes at Frame. I go to the one near our offices on Berners Street. There is a Hershesons hair salon above it, so you can get your hair done afterwardsand you can also choose from one of the many amazing additional services, like DryBy nails, SumanBrows, Ministry of Waxing, etc. It is literally a mecca. Then, around the corner is Nicola Clarke for John Frieda; Nic has been coloring my hair forever and I visit there on a very regular basis for a top-up of blond.

Gut CheckIf you want nutritional support or a colonic, see Kaori Murphy at the Hale Clinic. She is amazing at getting your gut health on track. She is extremely strict with you, but gentle, too. I saw her for months at one pointevery Friday morning I had to go see her. She honestly changed my life.

Arabellas Votary skin-care range is so loved by makeup artistsprobably because her oils are really light and wearable; The frankincense line from Neals Yard Remedies is amazing, and their farm and manufacturing facility are spectacular; Sam McKnights Cool Girl Barely There Texture Mist makes you look and feel like Kate Moss; I love anything from The Body Shop the original renegade brand; Theres a new British hair-care brand based on Ayurveda called Chmpo, which is the Indian word for shampoo.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read more:
National Treasures: Millie Kendall Recommends the Best Beauty Buys London Has to Offer - NewBeauty Magazine

Recommendation and review posted by Bethany Smith

publication date: May. 1, 2020

Howard A. Skip Burris III, MD, FACP, FASCO

President, American Society of Clinical Oncology

President, Clinical Operations and Chief Medical Officer

Sarah Cannon, the Cancer Institute of HCA Healthcare

Associate, Tennessee Oncology

This story is part of The Cancer Letters ongoing coverage of COVID-19s impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is availablehere.

The COVID-19 pandemic will change the structure and economics of clinical care and clinical trials in cancer, said Howard Skip Burris, president of clinical operations and chief medical officer of Sarah Cannon, the Cancer Institute of HCA Healthcare.

The pandemic is going to create an opportunity to look at how oncology should be reimbursed and how a practice is not disadvantaged when theyre able to function electronically in some areas, said Burris, who is this years president of the American Society of Clinical Oncology. And then I think bigger picture, this pandemic will help us set some health care priorities for the population.

Im hopeful that after we get through the storm, there will be a real assessment and look at the data as you alluded to about the need to continue with appropriate cancer screening programs, mammography, colonoscopy, and appropriate CT scans.

And hopefully, we wont see too big of a disadvantage coming from procedures being delayed. The information during this time will help confirm what we thought for yearsthat early detection of cancer really leads to better outcomes. These few months here, I think, are going to greatly shape how we approach health care over the next few years.

Burris spoke with Paul Goldberg, editor and publisher of The Cancer Letter.

Paul Goldberg:

First of all, how are you?

Skip Burris:

Im doing well. We are staying fairly busy in continuing to care for our patients. Nashville had a lot of cases, but we have had a fairly low number of hospitalizations and an even lower number of deaths. So, weve been a little bit of an outlier as a state.

Nashville had a lot of cases early, but the hospitals have been relatively quiet in comparison to other states. The major hospitals here have been running inpatient COVID-positive numbers in the twenties, with a handful of patients in the intensive care unit.

PG:

How about your practice? How about Sarah Cannon?

SB:

Our major practices are Tennessee Oncology and Florida Cancer Specialists, where we have the bulk of the patients on clinical trials. We also have research programs in Kansas City, Oklahoma City and Denver.

We have about a dozen COVID-19 positive patients across the practices, and have been fortunate that none have been critically ill. A few staff have been infected, exposed outside of our clinics, but again, nobody critically ill.

The Nashville clinic, where I practice, is relatively quiet, but we are continuing treatment. Surveillance visits have been moved out a few months, and were continuing to keep an eye on that timing. The benign hematology has also been moved out. The oral therapies are being handled with telemedicine and shipping the drugs to the patients.

The clinics across our network are steadily functioning, but not overly busy, including chemotherapy rooms. With the lower volume, we are able to successfully implement social distancing measures as well as all the safety precautions of masks, gloves, and hand washing.

PG:

What about the financial impact? Are you seeing any?

SB:

There is an impact, but its a little early to do any calculations. The absolute visits are going to be dropping. We are starting to pick up the telemedicine visits, but its probably 50/50 on patients being comfortable with that approach versus simply wanting to push out their visit. The treatments have remained fairly steady in terms of those patients that are on intravenous treatments.

I think the financial impact is not going to be quite as devastating as we had first anticipated. The missed visits will never be made up.

Its a little bit like the movies and the restaurant businesspeople are not going to have two dinners at the same place in the same night, or see two movies at the same timepatients are not going to come for two visits to our clinics in a week either. So, I think the financial impact is going to be substantial, but not catastrophic.

I do think it is different for large practices versus the smaller practices. I worry about some of the smaller practices, with a handful of physicians, and their ability to have staying power through this pandemic, as they may not have the ability to handle the decrease in volume.

PG:

What about impact on clinical trials, especially drug company trials? Weve certainly written a lot about NCI trials, but drug company trials, I think havent been really gauged yet. What impact do you think this will have on approvals?

SB:

Its an interesting question. We have seen big pharma that are conducting global trials pause studies and put a hold on accrual. I think a part of that is making sure that they can get the data.

Also, it was easier to not make site-specific selections and just put a large trial on hold. So, weve seen most of the big pharma react that way.

We have seen a substantial drop in enrollment for phase II/III studies, resulting from at least a third of the clinical trial menu being put on pause.

The other part about the phase II/III side of the businesses is, in many of those scenarios, patients have an option. We have had so many approvals recently. Patients may have an off-study option that might require fewer visits or less travel. I suspect that is impacting accrual as well.

All of those will be detrimental in terms of slowing down trial completion, slowing down approvals.

On the other hand, on the phase I end of the spectrum, where I think the majority of the patients are seeking an investigational treatment and/or a treatment to match their mutation, we have not seen quite the level of decline.

And in particular, we have seen the smaller biotechs continue forward. Many of their phase I trials are at only a handful of sites, making any decisions site-specific.

As you said at the beginning, in terms of approvals, certainly many of the phase II/III studies are going to be slowed substantially. It is also important to note that some of the big academic centers, typically accruing many patients, are in cities hit the hardest by COVID-19, such as New York City, Boston and some of the cities in Europe, which is impacting trials.

PG:

You would think that some patients would have to be censored out, because with time to progression, the radiographic metrics, you would pretty much have missed the opportunity to gauge it; right?

SB:

Correct. I think its going to be complex within the phase II/III trials. I was reading The Cancer Letter with Matt Ongs interview with Don Berry [The Cancer Letter, April 24, 2020], thinking about how individuals will need to come in and really think about how we pool that data and analyze it. But youre exactly right.

The NCI has been great in encouraging taking deviations related to COVID-19 needed to keep the patient on study. We have made a number of operational adjustments including remote data monitoring, shipping pills to keep people on oral therapies, and implementing telemedicine visits.

Certainly, in the phase II/III area, with time to progression studies, there will be an impact, and there will be some complexities in how we analyze that data.

PG:

How are academic cancer centers affected?

SB:

Probably a lot depends on where they are located geographically. In talking to our colleagues at centers in New York, Boston and New Haven, we know many of those centers have had to stop clinical trial accrual. We are seeing the same thing in much of the East Coast and parts of the West Coast.

Also, there is a tertiary referral travel population. We have seen, at all of our centers, patients being much more hesitant to travel for treatment. I think it will substantially impact analyzing the data from those centers and getting those trial programs up and running.

Some of the academic medical centers have had a higher volume of COVID-19 positive patients. I know Ive had some patients that have gone back and forth to MD Anderson, where they are now encouraging patients to stay there in Houston, and not travel for their safety.

This recommendation gets into socioeconomic issues about who can do this relocation and who cannot.

PG:

What impact do you think it will have financially on the academic cancer centers?

SB:

I think you have to look at an academic medical center as part of a larger hospital. We can break this into different bucketssmall community practices will be hit differently than larger community practices that have more synergies.

Larger practices may have better staying power, and, of course the CARES program allows the hospitals to help in some ways. There are some waivers with regard to Stark concerns, and then the ability for some of these practices to participate in the PPP programs for loans and for advanced Medicare payments.

When you think about the hospitals right now, they are essentially doing emergency room care, which has dropped, COVID-19 care thats ongoing, and then cancer care that needs to be done.

The other services generating revenues have slowed down because many of the procedures, such as orthopedics and cardiovascular can be pushed out a few months. We have seen across the country health systems and hospital systems beginning to furlough individuals and take other actions with regard to employment.

I think that this environment is going to be tough for the academic medical centers. Hospitals have multiple sources of revenue, and many of these sources have really been scaled back as patients choose to defer coming in or there are simply not the resources for routine health care.

PG:

So, there is redistribution, but is it a net loss?

SB:

It will be interesting to see how some of that care comes back. While patients will never make up that cancer visit, the patients who need a hip replacement will schedule their surgery.

The individuals who need a valve replacement will get their cardiac procedure. I think in other specialties there will be a backlog, and it will be interesting as we go through the summer and the fall to see how that is handled. There is some short-term pressure in terms of just how much routine health care has paused or slowed down.

It has been interesting to see the articles talking about all the patients who used to come into the emergency room or the urgent care centers for aches and pains, and how much that has dropped. And then we are going to wonder going forward, will patients be more hesitant to utilize the health care system? Will they think once or twice before coming in?

As you have alluded to, we also have the economic side: we are seeing the unemployment numbers go up, which may have short-term impact as well. We have many Americans, unfortunately, uninsured or with less health insurance than they have had in the past.

PG:

What about the impact on community hospitals and for-profit hospitals?

SB:

Sarah Cannons parent company is HCA Healthcare, and they have committed to not laying off anyone through this crisis. HCA Healthcare is a large company, with the financial strength to support pandemic pay programs that will aid employees.

County hospitals or rural community hospitals are impacted on a different level. They already were under economic pressures. I suspect we may see some consolidation and closures of hospitals in rural settings or in places that are geographically disadvantaged.

That issue is going to be a stressor to the system. We already were trying to figure out how to do rural health care before the pandemic, and this crisis has certainly exacerbated the challenge.

Hospitals that do not have a large system to help alleviate some of the stress are going to be struggling to get through the near term.

PG:

I was just looking at what seems to be happening in the adjuvant care. There seems to be a shift to neo-adjuvantbecause of COVID. Is there data to support this in terms of safety and efficacy?

SB:

That is a great question, and I say that because I have asked the same question. In certain settings, such as HER2 positive breast cancer, there are a number of patients who would likely benefit from neoadjuvant therapy, as well as some triple-negative or locally advanced tumors.

There are likely other subsets of breast cancer and other diseases where neoadjuvant therapy makes sense. But by and large, you are correct, that during this COVID-19 crisis, many think it is better to put patients through chemotherapy versus surgery. And that has been greatly debated.

CMS came out with guidelines that put cancer surgery in the Tier Three category, and that seems reasonable. Our motto at Sarah Cannon has been that we are going to stay safe and stay the course.

We have seen a number of surgeries put off, but I do not think I have ever said to a patient with invasive cancer that their surgery is elective. Some are more urgent than others.

The system has made a quick shift to thinking that neoadjuvant therapy is the safest thing to do or the best thing to do, but there is not a lot of data to back that up in many settings. We have never really had clinical trials that showed that hormonal therapy was a great neoadjuvant treatment for the hormone-positive breast cancer. It is a real judgment call to put patients through chemotherapy, with myelosuppression and more in this setting.

There were some broad-based recommendations made from several societies that I found interesting, without a lot of data to back them up.

PG:

Will we learn from this, or will this be one of those societal experiments that we will never know the impact of?

Read more:
Skip Burris: These few months are going to shape health care in the coming years - The Cancer Letter

Recommendation and review posted by Bethany Smith

The world lost another brilliant actor, Irrfan Khan, on April 29, 2020. He was admitted to Mumbais Kokilben hospital intensive care unit, with a colon infection, the day prior. His condition deteriorated quickly and took a turn for the worse. He was 53 years old at the time of his death.

In 2018, he was diagnosed with a neuroendocrine tumor. This is a type of cancer that begins in specialized cells called neuroendocrine cells. These cells have similar traits to those of hormone-producing cells and nerve cells. Neuroendocrine tumors are rare and normally form in the appendix, pancreas, small intestine, rectum, or lungs.

Khan was born in Jaipur, Rajasthan, India, on Jan. 7, 1967. His full name at birth is Sahabzade Irrfan Ali Khan. He was an amazing cricket player. Khan was selected for the CK Nayudu Tournament. However, due to a lack of funds, he was unable to attend.

He decided to focus his attention on acting. The beloved actor earned himself a scholarship to the National School of Acting located in New Delhi, in 1984. His acting career started out in Bollywood where he was in Haasil, Maqbool, and the Namesake to name a few movies.

Khan showed the world how adaptive he was when he took on his various roles. His exquisite style showed the world a man who could be charming, clever, and at times maniacal and dangerous. During his decades-long career, he won his way into many fans hearts.

His rise to international fame came with his role in the movie Slumdog Millionaire. This movie won seven BAFTAs and eight Academy Awards. Khan also had memorable roles in other movies such as, Jurassic World, Life of Pi, and The Amazing Spiderman.

Many people went to social media to voice how Khan had touched them with his acting. He has left behind his beloved wife Supta, and their sons Ayaan and Babil.

By Sheena RobertsonEdited by Jeanette Vietti

Sources:

IMDB: Irrfan KhanMayo Clinic: Neuroendocrine tumorsIndian Express: Irrfan Khan (1967-2020): An actor whose brilliance made everything betterYahoo: Slumdog Millionaire and Life of Pi star Irrfan Khan dies at 53MSN: Irrfan Khan, Life of Pi, and Slumdog Millionaire Star Dies at 53The Daily Beast: Irrfan Khan, Life of Pi and Slumdog Millionaire Star, Dies at Age 53

Top and Featured Image Courtesy of Herry Lawfords Flickr Page Creative Commons LicenseInline Image by Bollywood Hungama Courtesy of Wikimedia Commons Creative Commons License

death, khan, Slumdog Millionaire, spot

Read this article:
Irrfan Khan, International Superstar, Passed Away at the Age of 53 - Guardian Liberty Voice

Recommendation and review posted by Bethany Smith

By its very definition, medicine saves lives by treating or preventing diseases. But now, some in the media are distorting its meaning to include abortion the ending of anothers life.

On April 28, The New York Times published a piece examining, Abortion by Telemedicine. In the story, health and science writer Pam Belluck cited several women who obtained abortions through TelAbortion, a telemedicine program that provides video consultations with abortion providers so that pregnant women can take abortion pills on their own without having to visit an actual clinic. Both TelAbortion and Belluck recognized the pills that cause abortion as medications.

One of the women interviewed for the piece, Ashley Dale, allowed the Times to sit in on her video consultation.

The doctor explained that two medicines that would be mailed to Ms. Dale would halt her pregnancy and cause a miscarriage, Belluck described.

Bellucks wording mirrored the abortion industrys embrace of euphemistic language surrounding abortion. But theres a difference: Medicine saves human lives; abortion ends them. Miscarriage isnt a choice; abortion is.

In order to distinguish from surgical abortion, many in the media refer to medication abortion as an abortion administered by pill. But only recently havemajor outlets begun using phrases such as abortion medication to call abortion itself a type of medicine.

Belluck described what happens in this particular type of abortion.

[D]octers explain that most women do not experience discomfort from mifepristone, which blocks a hormone necessary for pregnancy to develop, she wrote. Cramping and bleeding, resembling a heavy period, occur after the expulsion of fetal tissue caused by the second drug, misoprostol, which is taken up to 48 hours later.

Thats not how all doctors describe it. Dr. Anthony Levatino, an obstetrician-gynecologist who once performed more than 1,200 abortions, partnered with pro-life group Live Action in 2016 todetail abortion procedures. Medical abortion, he said, consists of two steps.

At the abortion clinic or doctors office, the woman takes pills which contain Mifepristone, or RU-486, he began. RU-486 blocks the hormone progesterone and causes the lining of the mothers uterus to break down, cutting off blood and nourishment to the baby.

In the second step, the woman takes Misoprostol, or Cytotec, a day or two later. Taken together, RU-486 and Misoprostol cause severe cramping, contractions, and often heavy bleeding to force the dead baby out of the womans uterus, he added.

If the abortion takes place at nine weeks, he said, her baby will be almost an inch long and she might even be able to distinguish his or her fingers and toes.

Even so, theNew York Timespiece regularly referred to these abortion pills as medication. One photo caption showed Ashley Dale taking medications that were mailed to her.

At one point, Belluck described how one woman went on an engagement photo shoot with her fianc after taking the first medication and then took the second medication that evening.

She continued to use the phrase medication and even the two-medication regimen in her piece.

Abortion through medication, first approved by the F.D.A. in 2000, is increasingly becoming womens preferred method, she wrote.

Or is it? Several of the women appeared to choose abortion because they felt like it was their only choice.

Dale, the first woman Belluck mentioned in her piece, said she would love to have another baby, but circumstances involving an estranged boyfriend had made the choice clear.

Another woman, Lee, decided to terminate the pregnancy because she had recently cut ties with her boyfriend after he was arrested on drug charges.

And Leigh, who self-identified as pro-life, turned to abortion because she has depression, which became so severe after she had a baby two years ago that she sometimes felt suicidal, wrote Belluck.

In a follow-up call after her abortion, Leigh said she felt compelled to abort no matter how much I hate myself, Belluck reported. Even now, when she sees another baby, she asks herself, Did I make the wrong choice?

I wanted to keep my baby, but I just couldnt, she added.

Abortion and medicine are opposing terms; not interchangeable ones. Medicine promotes the welfare of human beings and saves lives every day. Abortion destroys a life that, from the moment of conception,contains a unique set of DNA. Instead of being a disease to fight, the unborn child is a patient to protect.

But heres one thing that even themedia can agree on: An unborn babys heart often begins beating before a mother even knows shes pregnant. Abortion stops it.

Read the original:
Dear Media: Abortion Is Not Medicine - Townhall

Recommendation and review posted by Bethany Smith

Direct-to-consumer Genetic Testing Market Insights 2018, is a professional and in-depth study on the current state of the global Direct-to-consumer Genetic Testing industry with a focus on the Global market. The report provides key statistics on the market status of the Direct-to-consumer Genetic Testing manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2018-2025 global Direct-to-consumer Genetic Testing market covering all important parameters.

The report on the Direct-to-consumer Genetic Testing market provides a birds eye view of the current proceeding within the Direct-to-consumer Genetic Testing market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Direct-to-consumer Genetic Testing market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Direct-to-consumer Genetic Testing market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2644650&source=atm

The key points of the Direct-to-consumer Genetic Testing Market report:

The report provides a basic overview of the Direct-to-consumer Genetic Testing industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2018-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Direct-to-consumer Genetic Testing industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018-2025 market development trends of Direct-to-consumer Genetic Testing industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Direct-to-consumer Genetic Testing Industry before evaluating its feasibility.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2644650&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Direct-to-consumer Genetic Testing are included:

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Direct-to-consumer Genetic Testing market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Direct-to-consumer Genetic Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Direct-to-consumer Genetic Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Direct-to-consumer Genetic Testing market.The following players are covered in this report:23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull GenomesDirect-to-consumer Genetic Testing Breakdown Data by TypeDiagnostic ScreeningPrenatal, Newborn Screening, and Pre-Implantation DiagnosisRelationship TestingDirect-to-consumer Genetic Testing Breakdown Data by ApplicationOnlineOffline

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2644650&licType=S&source=atm

Reasons to Purchase this Report:

* Estimates 2018-2025 Direct-to-consumer Genetic Testing market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

See original here:
Potential Impact of COVID-19 on Direct-to-consumer Genetic Testing Market Growth, Size, Share and Forecast 2020-2059 Aminet Market Reports -...

Recommendation and review posted by Bethany Smith

BOSTON, April 28, 2020 /PRNewswire/ -- In their brand new report "COVID-19 Diagnostics", global market research firm IDTechEx benchmarked more than 100 commercial devices across various technologies, providing a deep insight into the technology trends and biotech innovations surrounding the COVID-19 global response. For more information on this report, please visit http://www.IDTechEx.com/COVID.

"You cannot fight a fire blindfolded. And we cannot stop this pandemic if we don't know who is infected. We have a simple message for all countries: test, test, test. Test every suspected case" - Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO).

Viruses were once known as "contagious living fluids", strange infectious substances capable of slipping through the finest of filters unnoticed. SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic is indeed slipping through every layer of society, leaving behind severe public health and economic crises. Unlike in the influenza pandemic in 1918, today we are better equipped to identify the elusive bug.

Since the full genome sequencing of the SARS-CoV-2, many national laboratories have identified the regions of the genome amenable for genetic testing. The golden standard adopted by national laboratories around the world following the WHO protocol to detect the virus in individuals, is based on detecting genetic material specific to SARS-CoV-2 viruses in a person's nasopharyngeal secretions. The main tool for such genetic tests is the Reverse Transcription Polymerase Chain Reaction (RT-PCR). Primer strands that hybridise specifically to the SARS-CoV-2 genome, together with fluorescent probes, help amplify and detect the viral load present in a patient. RT-PCR, normally performed in a real-time quantitative qRT-PCR machine for live fluorescent read-out, constitutes the core element of the testing effort being deployed at the moment across the globe. Clinical laboratories with the necessary equipment and technical know-how to perform RT-PCR are leading this diagnosis effort.

However, not all countries are prepared, neither logistically or with enough equipment and capacity. An important bottleneck is the short supply of certain ancillary reagents, such as RNA extraction kits. The shortage of such supplies and long processing time, has led to many laboratories to try to circumvent some steps in the protocol and to come up with new approaches to reach the testing targets that have been set by policymakers and healthcare officials.

The need for universal and massive testing across the population has led to a race for technology innovations for COVID-19 diagnostics. Point-of-care molecular diagnostics (POC MDx) are portable devices that perform molecular diagnosis away from central labs. Microfluidics is the key technology behind POC MDx, which controls the motion of small amounts of fluids in microchannels. Microfluidic cartridges enable the miniaturisation of devices and introduces automation in the sample handling and detection processes. Some POC MDx devices use isothermal amplification of nucleic acid as an alternative to PCR devices. Isothermal amplifaction bypasses the need of thermal cycling and reduces the detection time to just 5 min. Various isothermal amplifaction methods have been adopted for COVID-19 diagnostics. Complex design and unspecific amplification hinder the widespread use of this method. "COVID-19 Diagnostics" provides a deep insight and comparison into the technologies, innovations and current progress on POC MDx and isothermal amplification.

Apart from the time consuming thermal cycling, real-time fluorescent detection is another limitation for low-cost and portable diagnosis tools. Lateral flow assays, electrochemical detection and microbead-based arrays are integrated with PCR to detect the amplified genetic products. These hybrid systems enable faster, cheaper and palm-size devices at the expense of sensitivity and specificity. More recently, CRISPR-Cas (gene-editing tool based on speficifc gene recognition) and DNA sequencing techniques show the potential for highly sensitive and selective hybrid systems, as highlighted in "COVID-19 Diagnostics". For more information on this report, please visit http://www.IDTechEx.com/COVID or for the full portfolio of medical technology research available from IDTechEx please visit http://www.IDTechEx.com/LifeSci.

Resonating with the message of the WHO director general: "test, test and test", these innovations offer the tools to stop the current outbreak, as well as to prevent future outbreaks, by effective diagnostics and surveillance testing.

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy, contact research@IDTechEx.com or visit http://www.IDTechEx.com.

Media Contact:Jessica AbineriMarketing Coordinator press@IDTechEx.com+44(0)1223-812300

View original content to download multimedia:http://www.prnewswire.com/news-releases/fighting-the-covid-19-fire-with-molecular-diagnostics-new-idtechex-report-on-innovations-301048428.html

SOURCE IDTechEx

See the rest here:
Fighting The COVID-19 Fire With Molecular Diagnostics, New IDTechEx Report on Innovations - P&T Community

Recommendation and review posted by Bethany Smith

Global CNS Gene Therapy Market Analysis

Persistence Market Research, in a recently published market study, offers valuable insights related to the overall dynamics of the CNS Gene Therapy market in the current scenario. Further, the report assesses the future prospects of the CNS Gene Therapy by analyzing the various market elements including the current trends, opportunities, restraints, and market drivers. The COVID-19 analysis section within the report offers timely insights regarding the impact of the global pandemic on the market. The presented study also offers data regarding the business and supply chain continuity strategies that are likely to assist stakeholders in the long-run.

As per the report, the CNS Gene Therapy market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and exceed a value of ~US$ XX by the end of 2029. Some of the leading factors that are expected to drive the growth of the market include, focus towards research and development, innovations, and evolving consumer preferences among others.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/27514

Regional Outlook

The report scrutinizes the prospects of the CNS Gene Therapy market in different geographical regions. The scope of innovation, consumer behavior, and regulatory framework of each region is thoroughly analyzed in the presented study.

Distribution-Supply Channel Assessment

The report provides a thorough analysis of the different distribution channels adopted by market players in the global CNS Gene Therapy market along with the market attractiveness analysis of each distribution channel. The impact of the COVID-19 pandemic on the different distribution channels is enclosed in the report.

Product Adoption Analysis

key players and product offerings

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/27514

The report aims to address the following pressing questions related to the CNS Gene Therapy market:

Key Takeaways from the CNS Gene Therapy Market Report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/27514

Why Companies Trust PMR?

See the original post here:
CNS Gene Therapy Market to Slip Due to Delays in Production Amidst Coronavirus Outbreak Cole Reports - Cole of Duty

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass., May 1, 2020 /PRNewswire/ --Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced it will share the architecture and components of its Safe Workplace Function Tool (SWFT) Productivity Solution. The SWFT Solution was designed in response to the COVID19 pandemic to support a safe work environment while maintaining productivity in the lab.

The SWFT Solution is a web-based application built and integrated into Microsoft 365 that allows scientists to view and schedule lab-based activities including by date, time and lab location. SWFT promotes collaboration and coordination between teams by predicting scheduling and occupancy conflicts, which allows team members to adjust their schedules to promote social distancing in the lab and office.

"The SWFT Solution has enabled Obsidian to continue to generate critical data across our cytoDRiVE development programs, while maximizing the safety of our staff," stated Catherine Stehman-Breen, M.D., Chief Research and Development Officer at Obsidian. "We have already shared this technology with large pharmaceutical and small biotechnology companies who are interested in our SWFT Solution to get their labs back up and running. We believe that it is more important than ever before to leverage one another's expertise in order to overcome challenges as we work tirelessly to deliver meaningful outcomes to patients in need."

To create Obsidian's bespoke application, (1) a capacity analysis was conducted, taking into consideration lab space and occupancy levels, and (2) in collaboration with scientists, workflow recommendations were implemented to determine an appropriate shift schedule. These steps facilitated the development of a solution that enabled scientists to plan their experiments with specific lab locations and shifts, as well as be alerted to and prevent any over-capacity issues. Obsidian implemented four three-hour lab blocks, with thirty-minutes of cleaning time between blocks, over a seven-day work week, to ensure that coronavirus-related safety recommendations were met.

Celeste Richardson, Ph.D., Vice President of Cell Therapy of Obsidian, stated, "We have a commitment to our employees to keep the health and safety of our employees top of mind while they work to bring innovative therapies to patients. The development of the SWFT Solution perfectly demonstrates Obsidian's culture of teamwork, determination and innovation."

Obsidian's IT Partner, TRNDigital, is continuing to iterate the tool to ensure it continues to meet scientists' needs and can be made available to others. The solution has been expanded to include density planning in the Obsidian offices. In addition, the SWFT Solution is scalable and flexible to other laboratory setups.

The SWFT solution was developed in-house by Henry Rogalin, Data Scientist, under the leadership of Nic Betts, Head of IT and Facilities, and in collaboration with a safety and facilities capacity team led by Jillian Giguere, Senior Manager of Laboratory Operations, Facilities, and EHS. For more information on SWFT, submit this inquiry form. Informational sessions and training will be hosted as requested.

About Obsidian TherapeuticsObsidian Therapeutics is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company's initial applications focus on developing novel cell therapies for the treatment of cancer. Obsidian is headquartered in Cambridge, Mass. For more information, please visit http://www.obsidiantx.com.

Media Contact:Maggie BellerRusso Partners, LLCMaggie.beller@russopartnersllc.com646-942-5631

View original content to download multimedia:http://www.prnewswire.com/news-releases/obsidian-therapeutics-develops-and-shares-safe-workplace-productivity-solution-in-response-to-covid19-301050820.html

SOURCE Obsidian Therapeutics

See the rest here:
Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19 - P&T Community

Recommendation and review posted by Bethany Smith

Analysis of the Global Hemophilia Gene Therapy Market

The report on the global Hemophilia Gene Therapy market reveals that the market is expected to grow at a CAGR of ~XX% during the considered forecast period (2019-2029) and estimated to reach a value of ~US$XX by the end of 2029. The latest report is a valuable tool for stakeholders, established market players, emerging players, and other entities to devise effective strategies to combat the impact of COVID-19

Further, by leveraging the insights enclosed in the report, market players can devise concise, impactful, and highly effective growth strategies to solidify their position in the Hemophilia Gene Therapy market.

Research on the Hemophilia Gene Therapy Market Addresses the Following Queries

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2640005&source=atm

Competitive Landscape

The competitive landscape section offers valuable insights related to the business prospects of leading market players operating in the Hemophilia Gene Therapy market. The market share, product portfolio, pricing strategy, and growth strategies adopted by each market player is included in the report. The major steps taken by key players to address the business challenges put forward by the novel COVID-19 pandemic is discussed in the report.

Regional Landscape

The regional landscape section provides a deep understanding of the regulatory framework, current market trends, opportunities, and challenges faced by market players in each regional market. The various regions covered in the report include:

End-User Assessment

The report bifurcates the Hemophilia Gene Therapy market based on different end users. The supply-demand ratio and consumption volume of each end-user is accurately depicted in the report.

Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Hemophilia Gene Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hemophilia Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hemophilia Gene Therapy market.The following players are covered in this report:Spark TherapeuticsUltragenyxShire PLCSangamo TherapeuticsBioverativBioMarinuniQureFreeline TherapeuticsHemophilia Gene Therapy Breakdown Data by TypeHemophilia AHemophilia BHemophilia Gene Therapy Breakdown Data by ApplicationHemophilia A Gene TherapyHemophilia B Gene Therapy

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2640005&source=atm

Essential Findings of the Hemophilia Gene Therapy Market Report:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2640005&licType=S&source=atm

Go here to see the original:
Assessing the Fallout From the Coronavirus Pandemic Hemophilia Gene Therapy to Discern Steadfast Expansion During 2019-2053 - amitnetserver

Recommendation and review posted by Bethany Smith

Sarepta Therapeutics, Inc.s (NASDAQ:SRPT): Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The US$9.2b market-cap company announced a latest loss of -US$715.1m on 31 December 2019 for its most recent financial year result. As path to profitability is the topic on SRPTs investors mind, Ive decided to gauge market sentiment. In this article, I will touch on the expectations for SRPTs growth and when analysts expect the company to become profitable.

Check out our latest analysis for Sarepta Therapeutics

According to the 22 industry analysts covering SRPT, the consensus is breakeven is near. They expect the company to post a final loss in 2021, before turning a profit of US$716m in 2022. Therefore, SRPT is expected to breakeven roughly 2 years from today. How fast will SRPT have to grow each year in order to reach the breakeven point by 2022? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, SRPT may become profitable much later than analysts predict.

Im not going to go through company-specific developments for SRPT given that this is a high-level summary, but, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing I would like to bring into light with SRPT is its relatively high level of debt. Generally, the rule of thumb is debt shouldnt exceed 40% of your equity, which in SRPTs case is 83%. Note that a higher debt obligation increases the risk in investing in the loss-making company.

There are key fundamentals of SRPT which are not covered in this article, but I must stress again that this is merely a basic overview. For a more comprehensive look at SRPT, take a look at SRPTs company page on Simply Wall St. Ive also compiled a list of key factors you should look at:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the original post here:
When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Become Profitable? - Simply Wall St

Recommendation and review posted by Bethany Smith

DetailsCategory: AntibodiesPublished on Friday, 01 May 2020 15:04Hits: 468

Recommendation for approval based on results from pivotal Phase 3 MEDALIST and BELIEVE studies

PRINCETON, NJ & CAMBRIDGE, MA, USA I April 30, 2020 IBristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Reblozyl (luspatercept) for the treatment of:

This CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). If approved, Reblozyl would be the first erythroid maturation agent approved in the EU, representing a new class of therapy for eligible patients. The safety and efficacy results provided in the application are from the pivotal Phase 3 MEDALIST and BELIEVE studies, evaluating the ability of Reblozyl to effectively address anemia associated with MDS and beta thalassemia, respectively.

"Patients with myelodysplastic syndromes who experience anemia have limited treatment options, and some have been shown to not respond to available erythropoietin-based therapies," said Uwe Platzbecker, M.D., Head of Clinic and Policlinic for Hematology and Cell Therapy, Leipzig University Hospital and lead investigator of the MEDALIST study. If approved, the introduction of a new class of therapy in Reblozyl could provide a promising option to help relieve patients from the burden of regular transfusions to manage their disease.

Todays positive CHMP opinion of Reblozyl is an important milestone for adult beta thalassemia patients in the EU who have limited treatment options to address anemia, a serious consequence of the disease, said Maria Domenica Cappellini, M.D., Professor of Medicine, University of Milan, Fondazione IRCCS Ca Granda and lead investigator of the BELIEVE study. Reblozyl has the potential to significantly decrease the number of red blood cell transfusions patients need.

This decision by the CHMP is an important step towards making this first-in-class therapy an option for eligible patients with anemia due to beta thalassemia or myelodysplastic syndromes, said Diane McDowell, M.D., vice president, Hematology Global Medical Affairs, Bristol Myers Squibb. We, and our partners at Acceleron, look forward to the opportunity to make this treatment option available in the EU and are extremely appreciative of the patients, families and individuals who continue to help us progress important research in a range of serious diseases.

About MEDALIST

MEDALIST is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study evaluating the safety and efficacy of luspatercept plus best supportive care (BSC) versus placebo plus BSC in adults with IPSS-R-defined very low-, low- or intermediate-risk non-del(5q) myelodysplastic syndromes (MDS). All patients were red blood cell (RBC) transfusion-dependent and were either refractory or intolerant to prior erythropoiesis stimulating agent (ESA) therapy, or were ESA nave and unlikely to respond due to endogenous serum erythropoietin levels of 200 U/L, and had no prior treatment with disease modifying agents. Results of the MEDALIST trial were first presented during the Plenary Session of the 2018 American Society of Hematology (ASH) Annual Meeting and were selected for the Best of ASH. The New England Journal of Medicine published the MEDALIST trial results in January 2020.

About MDS

MDS are a group of closely related blood cancers characterized by ineffective production of healthy red blood cells, white blood cells and platelets, which can lead to anemia and frequent or severe infections. People with MDS who develop anemia often require regular blood transfusions to increase the number of healthy red blood cells in circulation. Frequent transfusions are associated with an increased risk of iron overload, transfusion reactions and infections. There are approximately 50,000 patients with MDS in the EU5 countries.

About BELIEVE

BELIEVE is a Phase 3, randomized, double-blind, placebo-controlled multi-center study comparing luspatercept plus BSC versus placebo plus BSC in adults who require regular RBC transfusions (6-20 RBC units per 24 weeks with no transfusion-free period greater than 35 days during that period) due to beta thalassemia. Results of the BELIEVE trial were first presented at the 2018 ASH Annual Meeting and selected for the Best of ASH. The New England Journal of Medicine published the BELIEVE trial results in March 2020.

About Beta Thalassemia

Beta thalassemia is an inherited blood disorder caused by a genetic defect in hemoglobin. The disease is associated with ineffective erythropoiesis, which results in the production of fewer and less healthy RBCs, often leading to severe anemia a condition that can be debilitating and can lead to more severe complications for patients as well as other serious health issues. Treatment options for anemia associated with beta thalassemia are limited, consisting mainly of frequent RBC transfusions that have the potential to contribute to iron overload, which can cause serious complications such as organ damage. Across the United States, Germany, France, Italy, Spain and the United Kingdom, there are approximately 17,000 patients with beta thalassemia.

About Reblozyl

Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, promotes late-stage red blood cell maturation in animal models. Bristol Myers Squibb and Acceleron are jointly developing Reblozyl as part of a global collaboration. Reblozyl is currently approved in the U.S. for the treatment of:

Reblozyl is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Please see full Prescribing Information for REBLOZYL

Bristol Myers Squibb: Advancing Cancer Research

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase patients quality of life, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and Immuno-Oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational chimeric antigen receptor (CAR) T-cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb Company and Juno Therapeutics, a Bristol-Myers Squibb Company.

About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Bristol Myers Squibb, are co-promoting REBLOZYL (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelofibrosis. Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial.

For more information, please visit http://www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

SOURCE: Bristol-Myers Squibb

More here:
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes |...

Recommendation and review posted by Bethany Smith

In the first article we looked at face masks (when do you need to where one and why?); in the second we looked at disinfection (which disinfectants work best?); and the third topic was social distancing (why is 2 metres considered to be a safe distance?) The subject matter for the fourth article was the lockdown and whether the idea of an 'immunity passport' is a good idea (which is probably isn't). For the firth dive into COVID-19 subjects, we look at where we are with vaccine development, what the most promising antivirals are, and what do the different tests for coronavirus do and how do they vary?In this article, the topic is testing, vaccines and other efforts to help to combat the disease.

A laboratory technician works on coronavirus samples at "Fire Eye" laboratory in Wuhan

STR, STR, AFP

A fluorescent antibody (DFA) stain reveals the presence of rabies viral antigen in a tissue sample harvested from a mandibular salivary gland, suspected of being infected with rabies.

CDC/PHIL

A nurse wearing blue gloves administers a vaccine into a male patient's arm.

Rhoda Baer (National Institutes of Health)

Images of COVID-19 released by US science agencies

John SAEKI, AFP

France has now detected a total of 11 cases of the novel coronavirus

JEFF PACHOUD, AFP/File

This opinion article was written by an independent writer. The opinions and views expressed herein are those of the author and are not necessarily intended to reflect those of DigitalJournal.com

Go here to read the rest:
Op-Ed: Where are we with the coronavirus vaccine? - Digital Journal

Recommendation and review posted by Bethany Smith

Complete study of the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market include , BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1695571/global-viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market

Segmental Analysis

The report has classified the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry.

Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Segment By Type:

, BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Segment By Application:

, BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market include , BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3350): https://www.qyresearch.com/settlement/pre/7293801c1b080b1ca9df50a1a2dc1483,0,1,global-viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market

TOC

1 Market Overview of Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing1.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Overview1.1.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Product Scope1.1.2 Market Status and Outlook1.2 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Region (2015-2026)1.4 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Historic Market Size by Region (2015-2020)1.5 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size Forecast by Region (2021-2026)1.6 Key Regions Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.1 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.2 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.3 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.5 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Industry Impact1.7.1 How the Covid-19 is Affecting the Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Industry1.7.1.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Business Impact Assessment Covid-191.7.1.2 Supply Chain Challenges1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-191.7.3.1 Government Measures to Combat Covid-19 Impact1.7.3.2 Proposal for Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Players to Combat Covid-19 Impact 2 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Overview by Type2.1 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Type: 2015 VS 2020 VS 20262.2 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Historic Market Size by Type (2015-2020)2.3 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Forecasted Market Size by Type (2021-2026)2.4 AAV2.5 Adenoviral2.6 Lentiviral2.7 Retroviral2.8 Plasmid DNA2.9 Other Vectors 3 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Overview by Type3.1 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application: 2015 VS 2020 VS 20263.2 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Historic Market Size by Application (2015-2020)3.3 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Forecasted Market Size by Application (2021-2026)3.4 Cancers3.5 Inherited Disorders3.6 Viral Infections3.7 Others 4 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Competition Analysis by Players4.1 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing as of 2019)4.3 Date of Key Manufacturers Enter into Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market4.4 Global Top Players Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Headquarters and Area Served4.5 Key Players Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Product Solution and Service4.6 Competitive Status4.6.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 BioReliance5.1.1 BioReliance Profile5.1.2 BioReliance Main Business and Companys Total Revenue5.1.3 BioReliance Products, Services and Solutions5.1.4 BioReliance Revenue (US$ Million) (2015-2020)5.1.5 BioReliance Recent Developments5.2 Cobra Biologics5.2.1 Cobra Biologics Profile5.2.2 Cobra Biologics Main Business and Companys Total Revenue5.2.3 Cobra Biologics Products, Services and Solutions5.2.4 Cobra Biologics Revenue (US$ Million) (2015-2020)5.2.5 Cobra Biologics Recent Developments5.3 Oxford BioMedica5.5.1 Oxford BioMedica Profile5.3.2 Oxford BioMedica Main Business and Companys Total Revenue5.3.3 Oxford BioMedica Products, Services and Solutions5.3.4 Oxford BioMedica Revenue (US$ Million) (2015-2020)5.3.5 UniQure Recent Developments5.4 UniQure5.4.1 UniQure Profile5.4.2 UniQure Main Business and Companys Total Revenue5.4.3 UniQure Products, Services and Solutions5.4.4 UniQure Revenue (US$ Million) (2015-2020)5.4.5 UniQure Recent Developments5.5 FinVector5.5.1 FinVector Profile5.5.2 FinVector Main Business and Companys Total Revenue5.5.3 FinVector Products, Services and Solutions5.5.4 FinVector Revenue (US$ Million) (2015-2020)5.5.5 FinVector Recent Developments5.6 MolMed5.6.1 MolMed Profile5.6.2 MolMed Main Business and Companys Total Revenue5.6.3 MolMed Products, Services and Solutions5.6.4 MolMed Revenue (US$ Million) (2015-2020)5.6.5 MolMed Recent Developments5.7 MassBiologics5.7.1 MassBiologics Profile5.7.2 MassBiologics Main Business and Companys Total Revenue5.7.3 MassBiologics Products, Services and Solutions5.7.4 MassBiologics Revenue (US$ Million) (2015-2020)5.7.5 MassBiologics Recent Developments5.8 Richter-Helm5.8.1 Richter-Helm Profile5.8.2 Richter-Helm Main Business and Companys Total Revenue5.8.3 Richter-Helm Products, Services and Solutions5.8.4 Richter-Helm Revenue (US$ Million) (2015-2020)5.8.5 Richter-Helm Recent Developments5.9 FUJIFILM Diosynth Biotechnologies5.9.1 FUJIFILM Diosynth Biotechnologies Profile5.9.2 FUJIFILM Diosynth Biotechnologies Main Business and Companys Total Revenue5.9.3 FUJIFILM Diosynth Biotechnologies Products, Services and Solutions5.9.4 FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) (2015-2020)5.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments5.10 Lonza5.10.1 Lonza Profile5.10.2 Lonza Main Business and Companys Total Revenue5.10.3 Lonza Products, Services and Solutions5.10.4 Lonza Revenue (US$ Million) (2015-2020)5.10.5 Lonza Recent Developments5.11 Aldevron5.11.1 Aldevron Profile5.11.2 Aldevron Main Business and Companys Total Revenue5.11.3 Aldevron Products, Services and Solutions5.11.4 Aldevron Revenue (US$ Million) (2015-2020)5.11.5 Aldevron Recent Developments5.12 Eurogentec5.12.1 Eurogentec Profile5.12.2 Eurogentec Main Business and Companys Total Revenue5.12.3 Eurogentec Products, Services and Solutions5.12.4 Eurogentec Revenue (US$ Million) (2015-2020)5.12.5 Eurogentec Recent Developments5.13 Cell and Gene Therapy Catapult5.13.1 Cell and Gene Therapy Catapult Profile5.13.2 Cell and Gene Therapy Catapult Main Business and Companys Total Revenue5.13.3 Cell and Gene Therapy Catapult Products, Services and Solutions5.13.4 Cell and Gene Therapy Catapult Revenue (US$ Million) (2015-2020)5.13.5 Cell and Gene Therapy Catapult Recent Developments5.14 Biovian5.14.1 Biovian Profile5.14.2 Biovian Main Business and Companys Total Revenue5.14.3 Biovian Products, Services and Solutions5.14.4 Biovian Revenue (US$ Million) (2015-2020)5.14.5 Biovian Recent Developments5.15 Brammer Bio5.15.1 Brammer Bio Profile5.15.2 Brammer Bio Main Business and Companys Total Revenue5.15.3 Brammer Bio Products, Services and Solutions5.15.4 Brammer Bio Revenue (US$ Million) (2015-2020)5.15.5 Brammer Bio Recent Developments5.16 VGXI5.16.1 VGXI Profile5.16.2 VGXI Main Business and Companys Total Revenue5.16.3 VGXI Products, Services and Solutions5.16.4 VGXI Revenue (US$ Million) (2015-2020)5.16.5 VGXI Recent Developments5.17 PlasmidFactory5.17.1 PlasmidFactory Profile5.17.2 PlasmidFactory Main Business and Companys Total Revenue5.17.3 PlasmidFactory Products, Services and Solutions5.17.4 PlasmidFactory Revenue (US$ Million) (2015-2020)5.17.5 PlasmidFactory Recent Developments5.18 bluebird bio5.18.1 bluebird bio Profile5.18.2 bluebird bio Main Business and Companys Total Revenue5.18.3 bluebird bio Products, Services and Solutions5.18.4 bluebird bio Revenue (US$ Million) (2015-2020)5.18.5 bluebird bio Recent Developments5.19 Novasep5.19.1 Novasep Profile5.19.2 Novasep Main Business and Companys Total Revenue5.19.3 Novasep Products, Services and Solutions5.19.4 Novasep Revenue (US$ Million) (2015-2020)5.19.5 Novasep Recent Developments5.20 Spark Therapeutics5.20.1 Spark Therapeutics Profile5.20.2 Spark Therapeutics Main Business and Companys Total Revenue5.20.3 Spark Therapeutics Products, Services and Solutions5.20.4 Spark Therapeutics Revenue (US$ Million) (2015-2020)5.20.5 Spark Therapeutics Recent Developments5.21 Vigene Biosciences5.21.1 Vigene Biosciences Profile5.21.2 Vigene Biosciences Main Business and Companys Total Revenue5.21.3 Vigene Biosciences Products, Services and Solutions5.21.4 Vigene Biosciences Revenue (US$ Million) (2015-2020)5.21.5 Vigene Biosciences Recent Developments 6 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application6.1 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)6.2 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 7 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application7.1 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)7.2 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 8 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application8.1 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)8.2 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 9 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application9.1 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 10 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application10.1 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)10.2 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 11 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application11.1 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 12 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the rest here:
Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market 2020: Analysis By Regional Outlook, Competitive Landscape, Strategies And...

Recommendation and review posted by Bethany Smith

CHELMSFORD May 1, 2020 (Thomson StreetEvents) -- Edited Transcript of Brooks Automation Inc earnings conference call or presentation Thursday, April 30, 2020 at 8:30:00pm GMT

* Lindon G. Robertson

Brooks Automation, Inc. - Executive VP & CFO

Brooks Automation, Inc. - Director of IR

* Stephen S. Schwartz

* J. Ho

Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector

* Jacob K. Johnson

Crdit Suisse AG, Research Division - MD, Global Technology Strategist and Global Technology Sector Head

Janney Montgomery Scott LLC, Research Division - MD, Head of Healthcare Research & Senior Equity Research Analyst

Greetings, and welcome to the Brooks Automation Q2 2020 Financial Results. (Operator Instructions) As a reminder, this conference is being recorded Thursday, April 30, 2020. I would now like to turn the conference over to Mark Namaroff. Please go ahead.

Mark Namaroff, Brooks Automation, Inc. - Director of IR [2]

Thank you, Malaika. Good afternoon everyone on the line today. We hope everyone is staying healthy in this environment. We'd like to welcome you to our earnings conference call for the second quarter of fiscal 2020. Our Q2 earnings press release was issued after the close of the market today and it is available on our Investor Relations website located at brooks.investorroom.com, as are the supplementary PowerPoint slides that we'll be using during the prepared remarks.

I would like to remind everyone that during the course of the call today, we will be making a number of forward-looking statements within the meaning of the Private Litigation and Securities Act of 1995. There are many factors that may cause actual financial results or other events to differ from those identified in such forward-looking statements. I would refer you to the section of our earnings release titled Safe Harbor Statement, the safe harbor slide on our aforementioned PowerPoint presentation on our website, and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today.

We would also refer to a number of non-GAAP financial measures, which are used in addition to and in conjunction with results presented in accordance with GAAP. We believe non-GAAP measures provide an additional way of viewing aspects of our operations and performance. But when considered with GAAP financial results, the reconciliation of GAAP measures, and a reconciliation of GAAP measures, they provide an even more complete understanding of the Brooks business. Non-GAAP measures should not be relied upon to the exclusion of GAAP measures themselves.

On the call with me today is our President and Chief Executive Officer, Steve Schwartz, and Executive Vice President and Chief Financial Officer, Lindon Robertson. We will open the call up with remarks from Steve on the highlights of the second quarter, and then Lindon will provide a more detailed look into our financial results for the quarter and our outlook for the third fiscal quarter of 2020. We will then have time to take your questions at the end of our prepared remarks.

And with that, now I'd like to turn the call over to our CEO, Steve Schwartz.

--------------------------------------------------------------------------------

Stephen S. Schwartz, Brooks Automation, Inc. - CEO, President, Interim GM of Life Sciences & Director [3]

--------------------------------------------------------------------------------

Thank you, Mark, and good afternoon, everyone. We're glad to have you with us today. As we've already published preliminary results in a press release we issued on April 13th, I'll recap those results briefly and focus my remarks on some extra color at the segment level to give you some indication about how we see the current and near term business environment.

I'd like to start by discussing our priorities during this pandemic. First is the safety and wellbeing of our employees and their families as well as our partners including our suppliers and customers. Second, our ability to serve our customers that are deemed essential businesses with specific focus on any and all COVID-19 requests. And there have been many. And finally, the ongoing health of the company for the long term and actions we're taking to ensure that we emerge from this crisis stronger than ever.

With the exceptions of only a few brief work interruptions, all of our 20 plus factories, laboratories and repair centers were up and running throughout Q2 and all are currently operating. Of our approximately 3,300 global employees, about 1,800 have jobs that require them to be onsite. The rest of our employees are working from home. We are particularly proud of the way that each and every employee has embraced the new work practices that include social distancing, the diligent use of PPE, temperature screenings, staggered shifts and other practices which have allowed us to continue serving customers. All have adapted to this new work environment and we could not be more pleased with the resiliency of our operations during these turbulent times.

We consistently met our delivery commitments to customers as they struggled with their supply chains. And in many instances on the Life Sciences side, we stepped up to provide GENEWIZ, Sample Management and Informatic Services to customers who had either lost their regular services providers or who needed new services from us that came about because of the COVID-19 crisis. It's been energizing to bring even more capability to our customers and their need for our services underscores our purpose and mission.

Finally, we're building this company for the long term and our quarter to quarter and year to year revenue and earnings growth speaks to the momentum that we've generated. We've amassed an incredible technology and scientific portfolio, a global presence that allows us to deliver our world class capability to customers around the world, and we possess market positions in trusted brands that are the envy of our competitors. We've accomplished this through the energy and commitment of our global workforce. They know just how to ensure that we deliver on our long-term goals.

There is so much opportunity in front of us and it would be shortsighted of us to slow down now, especially since the capability we're building will be even more valuable in the future. For that reason, we intend to retain our team and fund their activities for technology development, new discovery, market capture, and customer support.

With each day that goes by, we're taking actions and making investments to emerge from the pandemic even stronger and more necessary to our customers. Our decision to continue these investments will have some impact on our earnings performance through the rest of this year, but we believe that it's absolutely the right action to take.

As companies and countries are contemplating how to reemerge from the pandemic, we have a definitive plan in place and a dedicated team that will continue to drive the momentum that we've established.

Now I'll report on Q2. Second quarter performance was strong with revenue of $220 million, up 11% year-over-year with the same 11% growth for each of our Semiconductor and Life Sciences segments. As I mentioned, for the most part our factories and laboratories were running throughout the quarter as we worked to meet customer demand, albeit it with many adjustments to mix because of both supply and demand changes throughout the quarter.

I'll begin with Life Sciences which delivered strong results with $95 million in revenue, up 4% sequentially with growth coming from both GENEWIZ and Sample Management. As each of these subsegments witnessed its own dynamics, I'll cover them separately starting with GENEWIZ.

Once again, GENEWIZ outperformed even our expectations, delivering a 25% year-over-year increase in revenue to $41 million. We were advantaged by our unique capability as both readers and writers of genes which allowed us to overcome some of the curveballs thrown our way. First, in early February when we announced our Q1 results, we told you that except for a team of scientists who remained onsite in support of urgent COVID-19 research, our Suzhou, China operations were basically shut down. It's in our Suzhou site where we perform the vast majority of our gene synthesis. Although we were bracing for what could have been a prolonged slowdown, China operations came back much faster than we'd imagined. By the end of February, more than 90% of our employees were back at work. And even without recovery in academia in China, demand from global customers was strong. In fact, despite the speedbump in February, the March quarter was a record for synthesis at just over $10 million.

Similarly, in next generation sequencing, we also had a record quarter with year-over-year growth of 46% and consistent 7% sequential growth, but with more volatility as the quarter progressed. We saw a normal pattern for NGS demand in the first two months of the quarter and then something of a spike in orders in the first half of March followed by two weeks of lower order volume. As we assess the NGS and synthesis businesses, we believe that much of the Q2 increase was the result of our normal customer capture. At the same time, it appears that some of the March burst came from researchers who no longer had capacity from their core laboratories or were facing reduced productivity from their existing suppliers while GENEWIZ remained at full capability and was eager to serve.

That said, order patterns for April have been steady but slightly lower in both synthesis and NGS but we have mixed signals as customer engagement for both synthesis and NGS projects remains quite active.

In Sanger sequencing, which is a high volume, overnight turns business where we perform millions of measurements for thousands of customers each quarter, revenue was steady for the first 10 weeks of the quarter. But when shelter in place orders closed many academic labs and caused a shutdown of nonessential research, we saw an abrupt reduction of more than 50% of our average daily volumes for the last two weeks of the quarter. And that level has persisted throughout most of April.

Though total Sanger revenue actually decreased slightly quarter-over-quarter, it was still up low single digits from Q2, one year ago. In Q3, we anticipate lower Sanger revenue until academic labs come back online and industry reaccelerates. And although we've seen average daily volumes increase during each of the past 4 weeks, we still remain below 50% of average. So at this point in the quarter, it would be too early to say that we have any concrete signs of a meaningful return to work.

In terms of overall GENEWIZ outlook, we expect business to be slightly down until academic researchers return to their benches and the activities that support clinical trials are back on the upswing. We don't have a prediction for when that will be, but we modeled a gradual return toward more normal volumes as we make our way through the rest of this quarter.

A difficult environment like the one we're in provides opportunities for companies that are prepared. In Q2, customers challenged us with hundreds of COVID-19 projects that gave us opportunities to demonstrate our incredible scientific acumen, round-the-clock collaboration, and fast turn, high quality results in support of their essential research. In addition, we took on many new urgent projects for first time customers. We believe that over the long run, it's this attention to solving customer issues that cement them to us and enabled GENEWIZ to add more than 200 new customers in the quarter.

Now I'll turn to Sample Management which even with all the disruption from coronavirus came in right on forecast I remind you that this year in Sample Management we have two areas of focus. A return to double digit revenue growth and sustainable gross margin improvement. And we're pleased with our progress against these goals. Even in this environment, Q2 was a very solid quarter. Revenue came in at $54 million, up 5% from Q1 and 3% year-over-year. Moreover, gross margin was up another 290 basis points from Q1. We're very encouraged by these results and it gives us confidence that this business is solidly on a path to be able to deliver on our expectations.

At the time we announced Q1 results, we knew two things. That the changes we had made to the organization structure and our focus on performance were set to deliver more growth and keep us on our trajectory for reacceleration of revenue in 2020, and that we were on track to deliver more profitability improvements.

That said, we also mentioned to you that we could foresee approximately $2 million of potential headwind from the coronavirus because of the inability of our field teams to complete system startups and perform revenue generating service on our equipment. Unfortunately, our customers obviously did not open for our employees and we did incur the headwinds that we had built into our forecast.

That said, there were many accomplishments in the quarter and I do want to highlight a few as they relate to trends in the business. Our cryogenics cold-chain products continue to make strong progress. Revenue topped $3 million in the quarter and we shipped B3C Cryo systems to 9 different customers. Six of those were repeat buyers. To date, 3/4 of our systems have been sold into cell and gene therapy applications and the momentum for these automated solutions continues to build.

In spite of the significant slowdown in clinical trial activity in March, Q2 Bio Storage activity generated our largest sample intake quarter since 2017, and we're encouraged by the reinvigoration of our customer capture activities. And in our consumables and instruments business lines, we made fast turn capital addition to respond to increased volume of consumables that will be used for COVID-19 tests as part of packages that we sell to diagnostics companies. This added capacity should allow us to increase revenue in Q3.

All-in, it was a very good quarter for Sample Management. Even with some COVID-19 related delays, revenue growth was right on track, profitability was ahead of schedule, and the result of our deliberate action is something that we'll build upon. The team is energized and active and we plan to come out of the COVID-19 days stronger than ever. What energizes us even more is the amount and level of large customer, large deal activity that's underway. During these days of no travel, our customer engagement activity has moved to the internet and deals that we've been working on for months are still being advanced. We are currently negotiating the final Ts and Cs on two large contracts and we have more multimillion dollar contracts in the pipeline. There opportunities speak to our capabilities and confidence to resume growth and profitability in this business.

On the semiconductor side, our performance in Q2 demonstrates the value of our product portfolio, and because of our close working relationship with our supply chain, we experienced only a small COVID-19 related revenue impact in the quarter which caused no impact to our customers. At $125 million in Q2, we established a new record high for quarterly semiconductor revenue and that's all the more remarkable because as an industry, we are still not back to our highs for semiconductor capital equipment spending. We attribute this outperformance to two factors. The strong high market share position of our Contamination Control Solutions business which satisfies a rapidly growing technology need, and continued design win and market share capture in our equipment automation products for OEM process equipment along with the steadily evolving advanced packaging market.

I'll give some specific color from our major Semiconductor business drivers, tool automation, advanced packaging and Contamination Control Solutions. Our automation products remained strong in the quarter with systems up approximately 10% and robots similar to last quarter's results. We had record bookings for our vacuum robots and vacuum systems, indicating demand remains very strong.

Sales to Chinese equipment manufacturers is picking up and this is a good indicator for both China fab activity and advanced packaging capability. We saw an uptick in advanced packaging in the quarter to just over $13 million or up 30% from Q1. This is still lower than one year ago, but it's the first sequential uptick in the last three quarters and in general a positive indicator. Based on order activity, we do have some indication that advanced packaging opportunities may be staring to percolate, especially in China.

Finally, I'll give a brief update on Contamination Control business which has been extremely strong as we delivered a record $45 million in revenue. The $45 million number is extremely significant for several reasons. First, we truly tested our supply chain and determined it to be very capable. In the first 2 quarters of 2020, we shipped as much revenue as in the last 3 quarters of 2019. And those were already healthy business levels.

Second, we met the demand for the expansion of the 5 Nanometer Foundry ramp on schedule and with very high quality. And finally, we continue to win additional business across a broad range of customers, device technologies that will serve us well as tier one foundry spending subsides.

Revenue in CCS will necessarily be lower in Q3 after two very strong back to back quarters, but still we expect healthy levels of more than $30 million in revenue which will be largely made up of a broader base of customers across different geographies and technology applications.

All-in, we're prepared for another strong quarter in our Semiconductor business. That said, we're also aware of some COVID-19 related supply chain issues that are slowing delivery of some parts. So far, we've been able to navigate through most of these issues, but it remains to be seen what the impact might be on actual demand from our customers. There's currently a lot of speculation as to the outlook for semiconductor processing equipment in 2020. Already our March quarter Semiconductor revenue was up 11% from one year ago and our Q2 Semiconductor book to bill was 1.2 for the quarter on a record revenue quarter. Depending upon June quarter capability of the global supply chain, our backlog and customer demand expectations would allow us to deliver yet another record quarter in June if we do not see any meaningful interruptions.

All-in, we had a very solid second quarter. We adjusted well as changes hit us and all companies. And we know that we'll need to rely on these same adaptive skills in the June quarter which may be even more uncertain. But already, we're well positioned and we're extremely confident in the long-term opportunities that we're diligently winning with all that we're investing today.

That concludes my formal remarks, and I'll turn the call now over to Lindon.

--------------------------------------------------------------------------------

Lindon G. Robertson, Brooks Automation, Inc. - Executive VP & CFO [4]

--------------------------------------------------------------------------------

Thank you, Steve. I'd like to refer your attention to the slides on our website, starting with Slide 3. Since Steve hit on these messages in his remarks, I will also be brief on what we see as the headlines of our performance. First, we had excellent momentum that has only modestly slowed by COVID-19 disruptions.

We have performed remarkably well with double digit year-over-year revenue growth in both segments and have established ourselves truly as a top reliable supplier in every market we serve.

Next, we expanded earnings substantially with continued performance enhancements in the Life Science segment. To put a finer point on it, gross margins in the Sample Management business are up nearly 600 basis points from a year ago. And third, we are well equipped for what lies ahead. Our liquidity is strong with $198 million of net cash on the balance sheet and healthy cash generation. To this point, our year-to-date cash flow from operations when you exclude the taxes paid on the sale of the semi cryo business, are $51 million. This a year-to-date improvement of $29 million over the prior year. The business is healthy and both sides are contributing growth, profit and cash flow.

Let's move onto Slide 4 to review the overall P&L. Let me first point you to the GAAP earnings and highlight what is different in that comparison. The growth of revenue and operating income is similar to that shown in the Non-GAAP profile on the right side. But what is different on the left side is in the tax line. If the first fiscal quarter, as guided under GAAP, we recognized a windfall tax benefit of approximately $6 million which is related to long term incentive stock units divested in the first quarter. That allowed deduction resulted in a net tax benefit of $3 million for the first fiscal quarter that in the second quarter is back to normal with the $3 million tax expense. The $6 million swing offsets the positive operating performance picture in the GAAP Profile.

In the Non-GAAP results, we apply this windfall to the projected tax rate and take it across the quarters of the fiscal year so that you can use the financials for a level performance indicator.

Continuing with the Non-GAAP performance on the right side, you can see the performance supported 48% year-to-year growth in earnings per share. Starting at the top, the revenue growth came similarly from each business with each growing 11% year to year. We saw a nice uptick in gross margins of 60 basis points sequentially, but Semiconductor gross margins remained approximately level from Q1 as expected. And the uptick was driven by Life Sciences improvement. On a year-over-year basis, the dynamics are also similar with improvement in Life Sciences and a bit softer margins in semiconductor. But all-in, gross margins continue to make progress and contribute to the bottom line.

Operating expenses during the quarter were up. On a sequential basis, the increase was in R&D for our Semiconductor business. Our engineering team has been kept busy throughout the COVID-19 environment, committed to advancing the projects with customers. On a year-over-year basis, operating expense was $7 million higher, driven by both R&D and SG&A. In the SG&A line, the growth was driven primarily around investments in Life Sciences including our IT transition to a single cloud based ERP platform, GENEWIZ growth, and some additional structure from our recent acquisition of RURO Software.

While we are spending some extra to keep our team in a safe environment and onboard with us through the COVID crisis, we anticipate reductions in travel expenses and G&A which will result in lower operating expense by approximately $1 million to $2 million in the third quarter. You can see operating margin expansion. Combining the growth with the margin expansion, you can also see Non-GAAP net income grew 51% year-over-year and expanded 11% sequentially.

Moving to below the operating income line, net interest expense was $600,000, lower by about $7 million compared with last year when we were carrying debt associated with the GENEWIZ acquisition. The non-GAAP tax rate for the quarter came in at about 23%, very consistent with our expectation of 21% to 25% for the year.

Let's turn now over to Slide 5 to discuss the segment results, starting with Life Sciences. In the second quarter, Life Sciences revenue grew 11% to $95 million compared with the second quarter last year. On an organic basis, Life Sciences grew 11% as well. This quarter was the first full year-over-year comparison which includes a full quarter of GENEWIZ revenue since the acquisition of the business in November of 2018. GENEWIZ had a strong second quarter with a revenue of $41 million, growing 25% from last year despite the impacts of COVID-19 as Steve addressed. As a reminder, our GENEWIZ China operations were largely closed down and observed strict quarantine restrictions from that Chinese New Year through February 10th. The exception to that were the labs from which GENEWIZ provided gene synthesis support for COVID-19 research customers. We estimated that the shutdown had an impact of approximately $2 million in the quarter. We are currently fully operational and demand from the China market has largely returned.

Sample Management provided 3% organic growth during the quarter in line with our expectation when we started the quarter. We had described and we did see about $2 million headwind from COVID-19 in the large store systems and post warranty services. This was due to some delays in an onsite installation and general lack of access to customer sites. But there were bright spots in Sample Management as well. Year-over-year growth was driven by cryo which more than doubled, and more substantively, Bio Storage services grew 7%. We have been very encouraged by the continued significant engagements and wins by the teams in the large storage business and in Bio Storage during this environment, fueling the path to return to double digit growth.

In addition, during the second quarter we acquired the Life Science Informatics Software firm RURO. RURO provides cloud-based software solutions to manage the laboratory workflow and bio sample data for a broad range of customers in the biotech, healthcare and pharmaceutical sectors. The business contributed approximately half a million of revenue in the time that we've owned them since mid-February.

As we announced in a March press release effective April 1st, we reorganized our Life Sciences business. We've combined the Bio Storage services with GENEWIZ, leveraging the common lab services and sample handling capabilities. This business combined is now $64 million of this quarter's $95 million business and showed year-to-year growth on that basis of 17%.

The remaining portion of the segment of Life Sciences is the Life Sciences products which was about $31 million and was up 1% year-over-year. If we had avoided the negative impact of the COVID-19 constraints, we estimate that the Life Science Products business would have grown about 4%.

Another bright spot in the quarter was on the gross margin line. The segment improved nicely in the second quarter up to 45.8%, up 330 basis points compared with last year. The year-over-year improvement was driven by the performance in Sample Management. In fact, we had improvement on every area of the business including our large TwinBank's store systems and services, the cryo systems, the consumables and instruments, and the Bio Storage services. This is driven by the performance improvements and cost reductions and the improved price management that's been implemented.

The growth of the segment and gross margin expansion covered the increased operating expense and drove 260 basis points of incremental operating margin year-over-year. The leverage of this business model and growth is fully evident on this page.

As we look into the third quarter, we are more cautious due to the continued and varied impacts of COVID-19. As Steve described, we've seen inside GENEWIZ sustained demand in synthesis, some volatility in the next generation sequencing, and a lower run rate from Sanger sequencing. Most notable to use is that continued absence of the academic research institutions and we have seen only a portion of the commercial teams return to full active status. And in Sample Management, it is unclear when customer sites will fully open around the world, limiting our access for installations and services. So at this point, we're expecting Life Sciences to deliver revenue in the range of $85 million to $91 million which is about 5% to 10% lower quarter-to-quarter.

Let's turn over to Slide 6 to review our Semiconductor business. Semiconductor Solutions revenue was $125 million for the second quarter, an increase of 5% sequentially and 11% year-over-year. If you were to look into the details of the quarter-to-quarter, you would see an uptick in the systems business which we ship primarily to tier two OEMs. I would highlight that the strength in that line in is the atmospheric systems as we expected. We do expect to see more vacuum systems coming in the second half which should assist gross margin.

The real story in the revenue line however is the strength of the Contamination Control Solutions which indeed ships to end user fabs. As referenced, these are record quarters for us in CCS and we continue to see expansion of qualifications and orders across many fabs. The rest of the Semiconductor story is in robots. While it is stable quarter-to-quarter, it is significantly higher year-over-year and our tier one OEM customers continue to call for additional output as we head into our second half.

It may appear we face no challenges in the second quarter, but in fact, the accomplishment reflects much diligence to coordinate supply availability, factory production and of course customer needs. We estimate that the negative impact to COVID-19 on revenue during the quarter for Semiconductor was approximately $5 million due to supply chain and the services challenges. On the positive side, these are delayed, not lost opportunities and due to the coordination efforts, our customers were not surprised nor disappointed by us.

Gross margins in Semi were similar to the prior quarter at about 40% and operating margins improved by 70 basis points. As mix improves in the second half, we expect gross margins to strengthen and if the market holds, growth will bring operating margins back upward on the leverage of the model.

Similar to the Life Science business, we're cautious about the outlook for the third quarter. We expect our supply chain will continue to face some issues. We also are sensitive that the broader supply chain of our customers aside from us affects the end user's timing for when they need our products. Finally, we know the impact of COVID-19 on the end markets can change rapidly. We expect our semiconductor business to deliver revenue in the range of $115 million to $124 million. This is approximately flat to lower -- I'm sorry, flat to down 8% quarter-to-quarter.

Let's turn now over to Slide 7 for a summary of our cash flow over the quarter. We generated $26 million of adjusted operating cash flow during the quarter. This excludes $92 million of income tax payments associated with a gain of the 2019 sale of our semiconductor cryo business. We also used approximately $16 million of cash for the acquisition of RURO as mentioned previously.

Our CapEx amounted to $12 million for the quarter, driven primarily by investments in operations and it includes approximately $1 million for the new GENEWIZ operation facility in Suzhou, China. Total uses of cash during the quarter totaled $105 million, and the change in net cash and equivalents during the quarter brings our cash, restricted cash and cash equivalents balance down to $249 million. The highlight here is the cash capability of the business we have built with GENEWIZ and subsequent to the divestiture of the semi cryo business. Year-to-date, as I said before, our operating cash flow when you exclude the tax on the gain in the sale, was $51 million or an increase of $29 million year-over-year.

On Slide 8, you will see a summary of the balance sheet. You can see at the top of the March 31st column we now carry $249 million in cash and marketable securities. With $51 million of debt, we have $198 million of net cash for operations and investments. This strong position provides us the fuel to invest for growth and gives us the confidence we will weather these uncertain times, and customers and our employees the confidence that we will sustain our investments.

Let's turn now to the summary on Slide 9. Fundamentals of the business are intact and we've gained customers and market share during these times. We have extended our leadership and continue preparing ourselves to be ready to accelerate when the recovery of the market. The balance sheet is strong, provides us the fuel for the journey and the strategic flexibility. We have seen growth momentum in each business. In Semiconductor we saw strong orders and have healthy backlog. But we also know the WFE CapEx environment comes down to the path which the chip makers decide to take. And in this time in particular, the OEM customers depend on a broad supply chain that is vulnerable.

Our Life Sciences business continues to win new business. The active markets of pharma, biotech and clinical continue to engage on improving their infrastructure with our capabilities and to request our support for the COVID research that they have stepped up to do themselves. So meanwhile, the academic research institutions have not returned to work yet and the timing of that return is uncertain and varied across the regions. So we find ourselves with unusually mixed signals. Good customer demand momentum, but uncertain market continuity in the near term. We have solid backlog but uncertain access to some customer locations. But there is one aspect that is very clear to us. We have the momentum with customers and the opportunity to delight them. If we keep that momentum with us, we will maintain our resources and be ready for the ramp as markets do fully return. In the short term, we are carrying some costs. We have some elements of our business less active during this time, but we're going to keep the team employed. We are providing premium pay for onsite labor, ensuring the PPE and clean facilities make a safe environment and expediting shipments to satisfy stressed delivery schedules. We will carry some so this cost in the short term and we will win additional customers as we are there for them throughout and we will be prepared for the full recovery ramp as the market returns to working order.

Let's cover that guidance for the third fiscal quarter of 2020. Revenue is expected to be in the range of $200 million to $215 million. Adjusted EBITDA is anticipated to be $26 million to $34 million and non-GAAP diluted earnings per share to be $0.16 to $0.24 per share. GAAP will be in the range of $0.04 to $0.12. For Life Sciences we factored in a return of the markets in the June month. This now concludes our prepared remarks, and I'll turn the call back over to Malaika, the Operator, to take questions from the line.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first phone question is from the line of Patrick Ho with Stifel. Please go ahead, your line is open.

--------------------------------------------------------------------------------

J. Ho, Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector [2]

--------------------------------------------------------------------------------

Thank you very much and hope everyone is well. And congrats on a really nice quarter in these challenging circumstances. Steve, maybe first off, in terms of the disruptions and the volatilities you've been seeing, can you give a little bit of color on your end how you were able to manage a very fluid environment and ensure that your top tier customers got what they needed? What were some of the steps you took? How did the business continuity plan work? If you could just give a little bit of color on that first.

--------------------------------------------------------------------------------

Stephen S. Schwartz, Brooks Automation, Inc. - CEO, President, Interim GM of Life Sciences & Director [3]

--------------------------------------------------------------------------------

Sure, Patrick, and thanks for the question on this. Specifically, on the Semi side, we give a lot of credit to the large OEM customers. They give us a good look at the business. And they adjust it quite frequently, so we're able to get out in front of the supply chain. And then our team managed the supply base extremely well. I think this is something over the past years that's become really fluid. When we get a signal from our tier one OEMs, we're able to transmit that quickly to our suppliers to get them prepared and I think the team managed it really well. It wasn't without problems for sure, but everybody knew how to accelerate and to get the job done. And Patrick, inside the company, everybody knows that deliveries to the customers are top priority, so if we go overtime, we spend. If we do something to get shipments there, we do it. And so I think it's a successful model that played out through the COVID period. And I think the business continuity plans that we have in place, we kicked them into action and I think they played out extremely well. I don't know that anybody could have anticipated the magnitude of what everybody was going to be faced with. But I think the team responded well. We're functioning completely differently just even two weeks into the shutdown period. Two weeks into the shutdown period we were operating with the same fluidity, but in a really different mode. So in general, the things that should have happened did. And we continue to manage going forward the supply base. There are air pockets we're finding coming from India, from Malaysia that we've been trying to work through now for the past 5 weeks. I think we're doing very well, but when you hear uncertainty from everybody in and around the supply chain, I think we're all dealing with the same kinds of things. But I do believe the team is in front of it and we seem to be weathering it pretty well.

--------------------------------------------------------------------------------

J. Ho, Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector [4]

--------------------------------------------------------------------------------

View post:
Edited Transcript of BRKS earnings conference call or presentation 30-Apr-20 8:30pm GMT - Yahoo Finance

Recommendation and review posted by Bethany Smith

In this report, the global Cancer Gene Therapy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Cancer Gene Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Cancer Gene Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Cancer Gene Therapy market to assist our clients arrive at beneficial business decisions.

The Cancer Gene Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Cancer Gene Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/2988

Resourceful insights enclosed in the report:

The major players profiled in this Cancer Gene Therapy market report include:

Some of the major companies operating in the global cancer gene therapy market are Cell Genesys, Advantagene, GenVec, BioCancell, Celgene and Epeius Biotechnologies. Other leading players in cancer gene therapy market include Introgen Therapeutics, ZIOPHARM Oncology, MultiVir and Shenzhen SiBiono GeneTech

Key points covered in the report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/2988

The market report addresses the following queries related to the Cancer Gene Therapy market:

The study objectives of Cancer Gene Therapy Market Report are:

To analyze and research the Cancer Gene Therapy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Cancer Gene Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Cancer Gene Therapy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Cancer Gene Therapy market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/2988

View original post here:
Coronavirus (COVID-19) Business Impact Mounting Prices of Coupled With Onset of Cost-effective Alternatives to Fuel the Growth of the Cancer Gene...

Recommendation and review posted by Bethany Smith

This essay first appeared on The MIT Reader on April 20, 2020

Across the world, many of us are imagining a possible rendezvous with Death. Some are turning to common addictions, such as alcohol and drugs. A study last week found that nearly 40 percent of remote-working New Yorkers are drinking while working, and one in five are stockpiling booze. Others arecoming together, figuratively speaking, to help those in great need. Still others are circling their wagons and loading up on more guns and ammo.

When circumstances jolt us from our routines, we grow unsettled and anxious. Some of us manage to resetsomehow grasping that business is not as usual, that time could be short. We manage to ask, What really matters now? For many, the answer is, help others.

Empathy and altruism are primordial human traits. When we wandered as foragers for 200,000 years, resources were iffy. So we smoothed out potentially fatal fluctuations by elaborating our instinct to share. But we didnt invent these circuits: A free rat, encountering a trapped rat, will make an effort to release it. And a rat, pulling a lever to obtain food pellets, will choose the lever that doesnt shock a stranger rat, even when that lever delivers two times less food. Thus neural circuits for empathy and altruism have likely been around since our last shared ancestor with rodentsnearly 100 million years.

Certain aspects of the neurobiology are clear. When we share our own resources to help a neighbor, they receive, besides practical aid, a pulse of dopamine from a core neural circuit that rewards every unexpected positive event. This neurochemical pulse evokes a pulse of good feeling, a momentary relief from seeking. Critically, this same circuit also rewards thegiver, thereby encouraging us to repeat that behavior in the iffy times to come. Living as we do now, this instinct to share has been little exercised. Multitudes in our cities have been lacking food and shelter, but they have been discounted as somehow undeserving. Otherwise, we would not have turned away for so long.

But now, suddenly,weare the needy, many desperate for sustenance and comfort. We encounter and welcome empathy and sharing, not just food and soap, but even our neighbors voices serenading us from their balconies. We recall such empathic, altruistic behaviors from earlier crises, such as urban blackouts, hurricanes, and floods. These behaviors provide dopamine beyond the givers and the receiversto all who share their emotionally uplifting stories. But what are we to make of the wagon-circlers? Whatisit with those people for whom sharing is neither a value nor a pleasure? They are numerous, so we should try to understand rather than write them off.

Empathy is a complex trait, like courage, or height. Traits are often partially inherited through our geneswith the degree of expression involving many genes with small effects. For height, for example, most people inherit roughly equal numbers of genes for short and for tall. Consequently, on the bell curve for height, they occupy the middlethey are average. Those who inherit more genes for short tend to be shorter than average, and those who inherit the opposite, more genes for tall, tend to be taller than average. When tall parents transmit abundant tall genes to their offspring, the occasional child may inherit 200 more genes for tall. If this child is male and well-fed, he may grow to seven and a half feet and play professional basketball. On the bell curve for height, he is far out on the tail.

Empathy has a substantial genetic contribution, about half as much as height, a group of researchers found in 2018. Inevitably, some individuals inherit more pro-empathy genes than average. Moreover, since they are likely to be born from empathic parents, such children will also witness empathic behaviors and be rewarded for performing them. Thus, learning and family values reinforce the pro-social neural circuitry. Such individuals are likely to become professional caregivers.

Inevitably, as well, some individuals inherit fewer pro-empathy genes than average and tend to feel less empathy. Moreover, since low empathy children are likely born from low empathy parents, they are less likely to witness empathic behaviors or be rewarded for performing them. An analogy would be short parents spawning short children and then starving them.

But why, since we evolved brain circuits for empathy, should any of us be deficient for this trait? Why cant we all be above average? Apparently, because our species success gains from individuals on both sides of the bell curve. Obviously, we benefit from individuals with high empathysharers and carers. But we also benefit from high functioning individuals with low empathy. Three thousand years ago King David was an awesome leader even as he coldheartedly sent his lovers husband to die in battle.

Low empathy individualslets face ithave appeal, which is why they succeed as politicians and media stars. They appeal especially to those of below-average empathy, that is, half of the population. For those of low empathy it can be thrilling to watch a leader without scruples live so close to who he really is. Unconstrained by others needs or feelings, he seems free. Whereas, those imbued with strong empathy are condemned to search continually for a sweet spot between the call of their own needs and those of others. Ironically, the empathizers may spend years in therapy trying to liberate their inner sociopath.

Now, in the shadow of COVID, neuroscience and genetics reminds us that for every human trait, there is a distribution. As we proceed to our empathic sweet spots, we have no choice but to accept it.

Link:
COVID-19 and the Harsh Reality of Empathy Distribution - Scientific American

Recommendation and review posted by Bethany Smith

Safety WarningDo Not Exceed Recommended Dose.When using nutritional supplements, please inform your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.This product is labelled to United States standards and may differ from similar products sold elsewhere in its ingredients, labeling and allergen warningsIndicationsINDICATIONS= Used to supplement ones diet, exercise routine, sports, weightlifting, cycling, running, strength training, conditioning, football, soccer, rugby, basketball, tennis, general well being! To increase ones strength and endurance in their workouts, exercise program or during any sport related activities.Legal DisclaimerWARNING: Consuming this product can expose you to chemicals including lead, which are known to the State of California to cause cancer. For more information go to http://www.P65Warnings.ca.gov/food.

Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.

Continue reading here:
Amazon.com: Life Extension Mega Green Tea Extract (Lightly ...

Recommendation and review posted by Bethany Smith

PC is not grumpy!

Editor:

This letter is in response to Sara Howells comments about PebbleCreek having an age discrimination problem. I have lived in PebbleCreek for almost seven years and have never had the problems she said she experienced.

First, and most importantly, PebbleCreek is a 55-and-older community. There is a certain amount of under-55 people allowed within the community, but most of the population is, yes, over 55! I dont know how Sara was ever allowed to rent in PebbleCreek being 37 years old unless it was done under the table! Why would she ever want to rent in this community being the age that she is? And Sara knew it was a 55-and-over community prior to moving in.

There must have been other circumstances for her being scolded for driving 21 mph in a 25 mph zone. Many people will drive that slowly and nothing is said to them. People even drive over the speed limit and do not get scolded unless caught by the patrol. So, the comment seems very jaded to me.

As far as her being aggressively screamed at for walking in an area that Im not supposed to be walking in, I would presume that to be the golf course. The person was probably playing golf, was quite a distance from her and yelled loud enough for her to hear and stop walking on the golf course. A 37-year-old, if it was the golf course, should have lived enough to know you never take a walk on a golf course, unless you are playing golf. If everyone did it the fairways would be damaged, etc. Her complaints have nothing to do with her being under 40. She was not following the rules of the community. Even a renter has an obligation to know and follow the community rules.

Renting to someone who is 37 is not stopping a house from being foreclosed upon. Most of the houses in PebbleCreek are paid for. The community has no problem with a person who pays her bills (we all do) or serves the community as an educator (there are many retired educators in the community myself included).

You were not preyed upon by people in this community. You were not following the rules. There are some grumpy individuals in the community, but the great majority of people are absolutely delightful! Before you criticize PebbleCreek as a community, get to know some people. You may change your mind. And if you continue to be unhappy in this age-restricted community, maybe you should find a nonage-restricted community to live in.

Barb Roberts

Goodyear

Review the rules

Editor:

This person was called out because of her behavior, not because of her age. There a many published rules and regulations in PebbleCreek that are designed to protect property and public safety. It is every residents responsibility to review these and adhere to them.

My sense is that the resident was driving well beyond the posted 25 mph speed limit when she was scolded. Did she brake quickly and then notice her speed? Was she distracted? Many PebbleCreek residents are in their 70s and 80s and do not have the quick reaction time of someone in their 30s.

Also, was she walking along the cart path on one of the golf courses when she was screamed at? For everyones safety, this is not allowed. This rule is in the HOA guidelines. Warning signs are not necessary or required. This is a golf course, not a carton of cigarettes. My sense is that this resident would be the first to sue the HOA if she were hit by a golf ball.

The vast majority of residents of PebbleCreek are here because of the outstanding population of great people from across the United States and Canada. We enjoy each other, our children and grandchildren when they visit us; the many activities provided to us; and living in a safe and vibrant community that is part of Goodyear.

We do not prey on those under 40.

Michael Quinn

Goodyear

Dont be so callous

Editor:

I just finished reading Charles Peabodys letter to the editor in the April 8 issue. What an astoundingly inaccurate piece of nonsense. Factually incorrect and appallingly callous.

Contrary to the claptrap on Facebook, COVID-19 is not a cold; it is a serious respiratory illness. According to his letter, a 1% serious illness rate is not a problem because most of the remaining 1% are susceptible to just about any medical issue due to their advanced age and preexisting conditions. That is factually incorrect. It is affecting people of all ages and is responsible for deaths in all age groups and physical conditions, although those with compromised immune systems and underlying disorders are more likely to die.

That said, Mr. Peabody seems to think thats acceptable if we can get people back to work and children back in school. He also said, Giving a couple thousand people their 87th Christmas is not much comfort to tens of millions of breadwinners who wont be able to afford holiday gifts Really? Hes worried about Christmas presents more than peoples lives? And this doozy: Maybe these elderly survivors will read one or two more books before they pass on It sounds like hed support just rounding up all us geezers and sending us to a camp to die and be done with us.

Its time for some real facts, as opposed to the alternative facts being spewed by the right and found on Facebook and other unverifiable social media sites. As of the morning of April 9, the mortality rate among infected people in the United States was about 3.53%. The population of the United States is about 330 million. That extrapolates to about 11.6 million deaths if everyone in the country is exposed to it. Even if we assume Mr. Peabodys 1% number is correct (which it isnt) that would still be 3.3 million deaths. I cant imagine any civilized society finding this acceptable for any reason, much less trading those lives for money. Remember, economies recover, but dead people dont.

Now some questions for Mr. Peabody and others who share his misguided opinions on this: Which elderly people in your family are you OK with dying for your convenience? What age would you arbitrarily establish as becoming officially expendable to the greater needs of the younger generation? How old are you and when will you be ready to consider yourself obsolete and redundant and make the sacrifice for the younger generation to make some money?

Lastly, his letter stated: Indeed COVID-19 itself is not virulent enough to have a lasting physical impact on our society. Thats not being an optimist; thats sticking your head in the sand.

Jude Clark

Buckeye

Scary philosophy

Editor:

Mr. Peabody carefully avoids the words death panel, but what other social function would fulfill his fantasy of considering the hypothetical benefits of giving aged and sickly people a slight life extension versus more comfort to breadwinners? He even tosses off the suggested age of 86 as the right age to sacrifice oneself to the economy. Well, that hits a little close to home for this family. Mr. Peabodys factual errors speak for themselves, but his philosophy should terrify his neighbors. I hope he keeps his death wishes away from our loved ones.

Jason Bentley

Litchfield Park

We are not one

Editor:

I love my country. I love the patriotic strains of the popular hymns America the Beautiful and others. I love the sense of unity assumed within the designation of American. When my kids were young, they asked me why I repeatedly viewed old WWII documentaries. Do you enjoy human suffering, dad? I replied no, but that I did enjoy the sense of unity among Americans at that time of stress and conflict. We were one.

Today we are not one, not just because we disagree in political opinion, but because we disagree on the cause and purpose of America; this is beyond disheartening. Hatred and self-loathing have since permeated our ranks in a most disagreeable manner. Hatred is corrosive, it clouds sound judgment, and prohibits ones ability to be objective and rational because it is emotionally driven.

Now, at this unprecedented time of pandemic displacement and uncertainty, it is refreshing that recent polls indicate a majority of Americans approve of the presidents efforts to address COVID-19 and economic issues since we all want America to succeed. There are some who seemingly do not want America to succeed. Rather than help and support, they impede and scorn, clearly driven by ugly hatred which blinds their eyes to fact, logic, liberty, free enterprise and patriotism. These hate-filled and ignorant comments are largely directed toward the president and his supporters. Supreme court justices have been threatened. The president is now being accused of crimes against humanity and second-degree murder,

Alec Baldwin going so far as to say, If you vote for Trump again you are mentally ill. Really? Can you imagine the backlash if a conservative had made such outlandish statements? How on Earth are we supposed to take the extreme left seriously? The ongoing leftist effort to overturn the 2016 election has morphed from ridiculous, to shameless unabashed absurdity, to the surreal because of personal hatred; if this president discovered a cure for cancer the left would villainize him and call for an inquiry. Friends, to disagree is American. But to hate, or support those that hate, is neither constructive nor respectable.

Jason Russell

Goodyear

Original post:
Lettters to the Editor | Opinion - westvalleyview.com

Recommendation and review posted by Bethany Smith

Complete study of the global Milk Thistle Health Tonic, market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Milk Thistle Health Tonic, industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Milk Thistle Health Tonic, production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Milk Thistle Health Tonic, market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold Milk Thistle Health Tonic

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1696541/covid-19-impact-on-global-milk-thistle-health-tonic-market

Segmental Analysis

The report has classified the global Milk Thistle Health Tonic, industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Milk Thistle Health Tonic, manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Milk Thistle Health Tonic, industry.

Global Milk Thistle Health Tonic, Market Segment By Type:

, Tablets, Capsules, Others Milk Thistle Health Tonic

Global Milk Thistle Health Tonic, Market Segment By Application:

Dietary Supplement, Health Food

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Milk Thistle Health Tonic, industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Milk Thistle Health Tonic, market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold Milk Thistle Health Tonic

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3900): https://www.qyresearch.com/settlement/pre/80683c606bc4072691a6b6f3cf0d15ff,0,1,covid-19-impact-on-global-milk-thistle-health-tonic-market

TOC

1 Study Coverage1.1 Milk Thistle Health Tonic Product Introduction1.2 Market Segments1.3 Key Milk Thistle Health Tonic Manufacturers Covered: Ranking by Revenue1.4 Covid-19 Implications on Market by Type1.4.1 Global Milk Thistle Health Tonic Market Size Growth Rate by Type1.4.2 Tablets1.4.3 Capsules1.4.4 Others1.5 Covid-19 Implications on Market by Application1.5.1 Global Milk Thistle Health Tonic Market Size Growth Rate by Application1.5.2 Dietary Supplement1.5.3 Health Food1.6 Coronavirus Disease 2019 (Covid-19): Milk Thistle Health Tonic Industry Impact1.6.1 How the Covid-19 is Affecting the Milk Thistle Health Tonic Industry1.6.1.1 Milk Thistle Health Tonic Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Milk Thistle Health Tonic Potential Opportunities in the COVID-19 Landscape1.6.3 Covid-19 Impact on Key Regions1.6.4 Proposal for Milk Thistle Health Tonic Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary2.1 Covid-19 Implications on Global Milk Thistle Health Tonic Market Size, Estimates and Forecasts2.1.1 Global Milk Thistle Health Tonic Revenue 2015-20262.1.2 Global Milk Thistle Health Tonic Sales 2015-20262.2 Covid-19 Implications on Global Milk Thistle Health Tonic, Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Milk Thistle Health Tonic Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Milk Thistle Health Tonic Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Covid-19 Implications on Global Milk Thistle Health Tonic Competitor Landscape by Players3.1 Milk Thistle Health Tonic Sales by Manufacturers3.1.1 Milk Thistle Health Tonic Sales by Manufacturers (2015-2020)3.1.2 Milk Thistle Health Tonic Sales Market Share by Manufacturers (2015-2020)3.2 Milk Thistle Health Tonic Revenue by Manufacturers3.2.1 Milk Thistle Health Tonic Revenue by Manufacturers (2015-2020)3.2.2 Milk Thistle Health Tonic Revenue Share by Manufacturers (2015-2020)3.2.3 Global Milk Thistle Health Tonic Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Milk Thistle Health Tonic Revenue in 20193.2.5 Global Milk Thistle Health Tonic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Milk Thistle Health Tonic Price by Manufacturers3.4 Milk Thistle Health Tonic Manufacturing Base Distribution, Product Types3.4.1 Milk Thistle Health Tonic Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Milk Thistle Health Tonic Product Type3.4.3 Date of International Manufacturers Enter into Milk Thistle Health Tonic Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Covid-19 Implications on Market Size by Type (2015-2026)4.1 Global Milk Thistle Health Tonic Market Size by Type (2015-2020)4.1.1 Global Milk Thistle Health Tonic Sales by Type (2015-2020)4.1.2 Global Milk Thistle Health Tonic Revenue by Type (2015-2020)4.1.3 Milk Thistle Health Tonic Average Selling Price (ASP) by Type (2015-2026)4.2 Global Milk Thistle Health Tonic Market Size Forecast by Type (2021-2026)4.2.1 Global Milk Thistle Health Tonic Sales Forecast by Type (2021-2026)4.2.2 Global Milk Thistle Health Tonic Revenue Forecast by Type (2021-2026)4.2.3 Milk Thistle Health Tonic Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Milk Thistle Health Tonic Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Covid-19 Implications on Market Size by Application (2015-2026)5.1 Global Milk Thistle Health Tonic Market Size by Application (2015-2020)5.1.1 Global Milk Thistle Health Tonic Sales by Application (2015-2020)5.1.2 Global Milk Thistle Health Tonic Revenue by Application (2015-2020)5.1.3 Milk Thistle Health Tonic Price by Application (2015-2020)5.2 Milk Thistle Health Tonic Market Size Forecast by Application (2021-2026)5.2.1 Global Milk Thistle Health Tonic Sales Forecast by Application (2021-2026)5.2.2 Global Milk Thistle Health Tonic Revenue Forecast by Application (2021-2026)5.2.3 Global Milk Thistle Health Tonic Price Forecast by Application (2021-2026) 6 North America6.1 North America Milk Thistle Health Tonic by Country6.1.1 North America Milk Thistle Health Tonic Sales by Country6.1.2 North America Milk Thistle Health Tonic Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Milk Thistle Health Tonic Market Facts & Figures by Type6.3 North America Milk Thistle Health Tonic Market Facts & Figures by Application 7 Europe7.1 Europe Milk Thistle Health Tonic by Country7.1.1 Europe Milk Thistle Health Tonic Sales by Country7.1.2 Europe Milk Thistle Health Tonic Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Milk Thistle Health Tonic Market Facts & Figures by Type7.3 Europe Milk Thistle Health Tonic Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Milk Thistle Health Tonic by Region8.1.1 Asia Pacific Milk Thistle Health Tonic Sales by Region8.1.2 Asia Pacific Milk Thistle Health Tonic Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Milk Thistle Health Tonic Market Facts & Figures by Type8.3 Asia Pacific Milk Thistle Health Tonic Market Facts & Figures by Application 9 Latin America9.1 Latin America Milk Thistle Health Tonic by Country9.1.1 Latin America Milk Thistle Health Tonic Sales by Country9.1.2 Latin America Milk Thistle Health Tonic Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Milk Thistle Health Tonic Market Facts & Figures by Type9.3 Central & South America Milk Thistle Health Tonic Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Milk Thistle Health Tonic by Country10.1.1 Middle East and Africa Milk Thistle Health Tonic Sales by Country10.1.2 Middle East and Africa Milk Thistle Health Tonic Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Milk Thistle Health Tonic Market Facts & Figures by Type10.3 Middle East and Africa Milk Thistle Health Tonic Market Facts & Figures by Application 11 Company Profiles11.1 Health Genesis11.1.1 Health Genesis Corporation Information11.1.2 Health Genesis Description, Business Overview and Total Revenue11.1.3 Health Genesis Sales, Revenue and Gross Margin (2015-2020)11.1.4 Health Genesis Milk Thistle Health Tonic Products Offered11.1.5 Health Genesis Recent Development11.2 Pure Encapsulations11.2.1 Pure Encapsulations Corporation Information11.2.2 Pure Encapsulations Description, Business Overview and Total Revenue11.2.3 Pure Encapsulations Sales, Revenue and Gross Margin (2015-2020)11.2.4 Pure Encapsulations Milk Thistle Health Tonic Products Offered11.2.5 Pure Encapsulations Recent Development11.3 Regis11.3.1 Regis Corporation Information11.3.2 Regis Description, Business Overview and Total Revenue11.3.3 Regis Sales, Revenue and Gross Margin (2015-2020)11.3.4 Regis Milk Thistle Health Tonic Products Offered11.3.5 Regis Recent Development11.4 Solgar11.4.1 Solgar Corporation Information11.4.2 Solgar Description, Business Overview and Total Revenue11.4.3 Solgar Sales, Revenue and Gross Margin (2015-2020)11.4.4 Solgar Milk Thistle Health Tonic Products Offered11.4.5 Solgar Recent Development11.5 Aksuvital11.5.1 Aksuvital Corporation Information11.5.2 Aksuvital Description, Business Overview and Total Revenue11.5.3 Aksuvital Sales, Revenue and Gross Margin (2015-2020)11.5.4 Aksuvital Milk Thistle Health Tonic Products Offered11.5.5 Aksuvital Recent Development11.6 BEC11.6.1 BEC Corporation Information11.6.2 BEC Description, Business Overview and Total Revenue11.6.3 BEC Sales, Revenue and Gross Margin (2015-2020)11.6.4 BEC Milk Thistle Health Tonic Products Offered11.6.5 BEC Recent Development11.7 NC11.7.1 NC Corporation Information11.7.2 NC Description, Business Overview and Total Revenue11.7.3 NC Sales, Revenue and Gross Margin (2015-2020)11.7.4 NC Milk Thistle Health Tonic Products Offered11.7.5 NC Recent Development11.8 Life Extension11.8.1 Life Extension Corporation Information11.8.2 Life Extension Description, Business Overview and Total Revenue11.8.3 Life Extension Sales, Revenue and Gross Margin (2015-2020)11.8.4 Life Extension Milk Thistle Health Tonic Products Offered11.8.5 Life Extension Recent Development11.9 Swisse11.9.1 Swisse Corporation Information11.9.2 Swisse Description, Business Overview and Total Revenue11.9.3 Swisse Sales, Revenue and Gross Margin (2015-2020)11.9.4 Swisse Milk Thistle Health Tonic Products Offered11.9.5 Swisse Recent Development11.10 HerbsofGold11.10.1 HerbsofGold Corporation Information11.10.2 HerbsofGold Description, Business Overview and Total Revenue11.10.3 HerbsofGold Sales, Revenue and Gross Margin (2015-2020)11.10.4 HerbsofGold Milk Thistle Health Tonic Products Offered11.10.5 HerbsofGold Recent Development11.1 Health Genesis11.1.1 Health Genesis Corporation Information11.1.2 Health Genesis Description, Business Overview and Total Revenue11.1.3 Health Genesis Sales, Revenue and Gross Margin (2015-2020)11.1.4 Health Genesis Milk Thistle Health Tonic Products Offered11.1.5 Health Genesis Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Milk Thistle Health Tonic Market Estimates and Projections by Region12.1.1 Global Milk Thistle Health Tonic Sales Forecast by Regions 2021-202612.1.2 Global Milk Thistle Health Tonic Revenue Forecast by Regions 2021-202612.2 North America Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.2.1 North America: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.2.2 North America: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.2.3 North America: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026)12.3 Europe Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.3.1 Europe: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.3.2 Europe: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.3.3 Europe: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.4.2 Asia Pacific: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Milk Thistle Health Tonic Market Size Forecast by Region (2021-2026)12.5 Latin America Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.5.1 Latin America: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.5.2 Latin America: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.5.3 Latin America: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Milk Thistle Health Tonic Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis14.2 Milk Thistle Health Tonic Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:
Milk Thistle Health Tonic, Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026| Health Genesis, Pure Encapsulations,...

Recommendation and review posted by Bethany Smith

Complete study of the global Covid-19 Impact on Milk Thistle Health Tonic market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Covid-19 Impact on Milk Thistle Health Tonic industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Covid-19 Impact on Milk Thistle Health Tonic production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Covid-19 Impact on Milk Thistle Health Tonic market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1696243/covid-19-impact-on-milk-thistle-health-tonic-market

Segmental Analysis

The report has classified the global Covid-19 Impact on Milk Thistle Health Tonic industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Covid-19 Impact on Milk Thistle Health Tonic manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Covid-19 Impact on Milk Thistle Health Tonic industry.

Global Covid-19 Impact on Milk Thistle Health Tonic Market Segment By Type:

, Tablets, Capsules, Others

Global Covid-19 Impact on Milk Thistle Health Tonic Market Segment By Application:

Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold, etc. Based on the Region:, Asia-Pacific (China, Japan, South Korea, India and ASEAN), North America (US and Canada), Europe (Germany, France, UK and Italy), Rest of World (Latin America, Middle East & Africa) Based on the Type:, Tablets, Capsules, Others Based on the Application:, Dietary Supplement, Health Food

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Covid-19 Impact on Milk Thistle Health Tonic industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Covid-19 Impact on Milk Thistle Health Tonic market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold, etc.

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3250): https://www.qyresearch.com/settlement/pre/84e80cd1f8c8895c98fd4fdc22d8c304,0,1,covid-19-impact-on-milk-thistle-health-tonic-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Milk Thistle Health Tonic Industry1.7 COVID-19 Impact: Milk Thistle Health Tonic Market Trends 2 Global Milk Thistle Health Tonic Quarterly Market Size Analysis2.1 Milk Thistle Health Tonic Business Impact Assessment COVID-192.1.1 Global Milk Thistle Health Tonic Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global Milk Thistle Health Tonic Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Milk Thistle Health Tonic Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 Global Milk Thistle Health Tonic Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global Milk Thistle Health Tonic Factory Price by Manufacturers3.3 Location of Key Manufacturers Milk Thistle Health Tonic Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into Milk Thistle Health Tonic Market3.5 Key Manufacturers Milk Thistle Health Tonic Product Offered3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Milk Thistle Health Tonic Segments, By Type4.1 Introduction1.4.1 Tablets1.4.2 Capsules1.4.3 Others4.2 By Type, Global Milk Thistle Health Tonic Market Size, 2019-20214.2.1 By Type, Global Milk Thistle Health Tonic Market Size by Type, 2020-20214.2.2 By Type, Global Milk Thistle Health Tonic Price, 2020-2021 5 Impact of Covid-19 on Milk Thistle Health Tonic Segments, By Application5.1 Overview5.5.1 Dietary Supplement5.5.2 Health Food5.2 By Application, Global Milk Thistle Health Tonic Market Size, 2019-20215.2.1 By Application, Global Milk Thistle Health Tonic Market Size by Application, 2019-20215.2.2 By Application, Global Milk Thistle Health Tonic Price, 2020-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Health Genesis7.1.1 Health Genesis Business Overview7.1.2 Health Genesis Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.1.3 Health Genesis Milk Thistle Health Tonic Product Introduction7.1.4 Health Genesis Response to COVID-19 and Related Developments7.2 Pure Encapsulations7.2.1 Pure Encapsulations Business Overview7.2.2 Pure Encapsulations Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.2.3 Pure Encapsulations Milk Thistle Health Tonic Product Introduction7.2.4 Pure Encapsulations Response to COVID-19 and Related Developments7.3 Regis7.3.1 Regis Business Overview7.3.2 Regis Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.3.3 Regis Milk Thistle Health Tonic Product Introduction7.3.4 Regis Response to COVID-19 and Related Developments7.4 Solgar7.4.1 Solgar Business Overview7.4.2 Solgar Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.4.3 Solgar Milk Thistle Health Tonic Product Introduction7.4.4 Solgar Response to COVID-19 and Related Developments7.5 Aksuvital7.5.1 Aksuvital Business Overview7.5.2 Aksuvital Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.5.3 Aksuvital Milk Thistle Health Tonic Product Introduction7.5.4 Aksuvital Response to COVID-19 and Related Developments7.6 BEC7.6.1 BEC Business Overview7.6.2 BEC Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.6.3 BEC Milk Thistle Health Tonic Product Introduction7.6.4 BEC Response to COVID-19 and Related Developments7.7 NC7.7.1 NC Business Overview7.7.2 NC Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.7.3 NC Milk Thistle Health Tonic Product Introduction7.7.4 NC Response to COVID-19 and Related Developments7.8 Life Extension7.8.1 Life Extension Business Overview7.8.2 Life Extension Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.8.3 Life Extension Milk Thistle Health Tonic Product Introduction7.8.4 Life Extension Response to COVID-19 and Related Developments7.9 Swisse7.9.1 Swisse Business Overview7.9.2 Swisse Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.9.3 Swisse Milk Thistle Health Tonic Product Introduction7.9.4 Swisse Response to COVID-19 and Related Developments7.10 HerbsofGold7.10.1 HerbsofGold Business Overview7.10.2 HerbsofGold Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.10.3 HerbsofGold Milk Thistle Health Tonic Product Introduction7.10.4 HerbsofGold Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis8.1 Milk Thistle Health Tonic Supply Chain Analysis8.1.1 Milk Thistle Health Tonic Supply Chain Analysis8.1.2 Covid-19 Impact on Milk Thistle Health Tonic Supply Chain8.2 Distribution Channels Analysis8.2.1 Milk Thistle Health Tonic Distribution Channels8.2.2 Covid-19 Impact on Milk Thistle Health Tonic Distribution Channels8.2.3 Milk Thistle Health Tonic Distributors8.3 Milk Thistle Health Tonic Customers 9 Key Findings 10 Appendix10.1 About Us10.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

The rest is here:
Covid-19 Impact on Milk Thistle Health Tonic Market 2020| Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand, Analysis by Top Leading...

Recommendation and review posted by Bethany Smith